The QualityStocks Daily Thursday, February 25th, 2021

Today's Top 3 Investment Newsletters

Tip.us(QPRC) +263.64%

Schaeffer's(PAND) +133.36%

QualityStocks(CDXC) +92.40%

The QualityStocks Daily Stock List

Akebia Therapeutics Inc. (NASDAQ: AKBA) (FRA: AX9)

MarketBeat, MarketClub Analysis, BUYINS.NET, StreetInsider, INO.com Market Report, TradersPro, Kiplinger Today, StockMarketWatch, Schaeffer's, Streetwise Reports, TraderPower, Marketbeat.com, The Street, StreetAuthority Daily, Zacks, Barchart, Investing Futures, The Online Investor, InvestorPlace, Trades Of The Day, Hit and Run Candle Sticks, Flagler Financial Group, Wealth Insider Alert and SmallCapNetwork reported earlier on Akebia Therapeutics Inc. (AKBA), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Akebia Therapeutics Inc. (NASDAQ: AKBA) (FRA: AX9) is a biopharmaceutical firm which is focused on developing and commercializing therapies for patients with kidney ailments. It is also involved in developing and commercializing drugs for the treatment of metabolic and renal disorders.

The firm, which is based in Cambridge, Massachusetts, was founded by Robert A. Shalwitz, Joseph H. Gardner, Josh P. Fairbank, Michael E. Pape and John M. Rice on Feb. 27, 2007. Akebia Therapeutics serves consumers in the United States.

Akebia Therapeutics has a collaboration agreement with Mitsubishi Tanabe Pharma Corporation and Otsuka Pharmaceutical Co. Ltd to develop and commercialize one of its candidates, vadadust, in the U.S., the Middle East, European Union, Canada, Russia, Australia and China as well as in Japan and other Asian nations. Additionally, the firm has a license and research agreement with Janssen Pharmaceutica NV for developing and commercializing HIF-prolyl hydroxylases-targeted compounds globally.

Akebia Therapeutics’ product portfolio includes vadadustat, which is currently in phase 3 development and is an oral therapy indicated for treatment of anemia in chronic kidney disease. Its other product candidate, Auryxia, has been developed to help control serum phosphorus levels in adult patients with chronic kidney disease, those on dialysis or the hyperphophatemia indication. The firm also develops AKB-5169, a preclinical compound indicated for treatment of inflammatory bowel disease.

Around 1.7 million individuals die annually due to acute kidney injury, so having alternative therapies in the market provides patients with viable options that may work when conventional therapies don’t.

Akebia Therapeutics Inc. (AKBA), closed Thursday's trading session at $3.47, off by 18.9252%, on 15225369 volume with 39,770 trades. The average volume for the last 3 months is 6,624,460 and the stock's 52-week low/high is $2.08999991/$13.71.

Color Star Technology Co. Ltd. (NASDAQ: CSCW) (FRA: 2J4)

InvestorsUnderground reported earlier on Color Star Technology Co. Ltd. (CSCW), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Color Star Technology Co. Ltd. (NASDAQ: CSCW) (FRA: 2J4) is a holding company that mainly operates as an education and entertainment firm, which offers offline and online music education services and entertainment performances.

Color Star Tech, formerly known as Huitao Technology Co. Ltd, was founded on September 1, 2005 and is based in New York. The firm changed its name in May 2020 and operates in China and the United States.

Through its subsidiaries, Color Star Tech focuses on the early childhood education service business, by providing a system to preschools and day cares across China, which include intellectual campus administration SaaS systems, robotic and artificial intelligence technologies as well as education planning.

In the music education and entertainment business, the firm offers intellectual property licensing and leases music performance equipment. Additionally, it provides Color World, an online platform for cultural entertainment that offers celebrity concert videos, celebrity lectures, artist interactive communication and celebrity peripheral products.

Color Star Tech recently entered a collaboration with 2 UAE firms, which would expand the company’s reach in the Middle East and boost their international presence, thus bringing them closer to their goal of becoming a global internet entertainment firm. This will be good for the firm’s growth as well as their stocks, as more exposure brings in more investments.

Color Star Technology Co. Ltd. (CSCW), closed Thursday's trading session at $0.8871, off by 13.0294%, on 4754798 volume with 8,940 trades. The average volume for the last 3 months is 9,145,266 and the stock's 52-week low/high is $0.311300009/$2.05999994.

ReTo Eco-Solutions Inc. (NASDAQ: RETO)

StreetInsider, StockMarketWatch and TraderPower reported previously on ReTo Eco-Solutions Inc. (RETO), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

ReTo Eco-Solutions Inc. (NASDAQ: RETO) is a distributor and manufacturer of eco-friendly building materials. The firm markets its products primarily in China but exports them as well.

ReTo Eco-Solutions is based in Beijing, the People’s Republic of China and was founded in 1999. The firm’s products include tiles, abrasives, pavers, asbestos, bricks, concretes and on-metallic mineral products.

The firm provides construction material manufacturing machinery, like automated production equipment with hydraulic integration in Southeast Asia, China, North Africa, South Asia, the Middle East and North America. It also offers construction solutions which include project installation, design and consultation.

ReTo Eco-Solutions’ materials are used for building walls, insulation and decoration, for hydraulic ecological projects like river transformation and slope protection, for slope construction, gardens, retaining walls, roads, city squares and bridges, and for water retention, water absorption and flood control. In addition to this, the firm assumes various municipal construction projects, which include landscaping, sponge city projects, as well as public plaza and sewage pipeline construction.

ReTo Eco-Solutions manufactures its products from fly-ash and mining waste, which demonstrates that it’s already green on a planet that is working towards living sustainably. Eco-friendly building materials are a thing as of the now as well as the future and as more countries around the globe move to renewable energies, so many may prefer to build using eco-friendly products that do not harm the environment. This makes ReTo to be well positioned to benefit from the growing awareness about the dangers posed by products made in a way that’s not sustainable.

ReTo Eco-Solutions Inc. (RETO), closed Thursday's trading session at $1.85, off by 19.9134%, on 2713510 volume with 8,558 trades. The average volume for the last 3 months is 4,053,175 and the stock's 52-week low/high is $0.300000011/$3.66000008.

Sunesis Pharmaceuticals Inc. (NASDAQ: SNSS) (FRA: RYIS), now Viracta Therapeutics, Inc. (Nasdaq: VIRX)

Greenbackers, Streetwise Reports, The Street, OTC Picks, Wall Street Resources, MicrocapVoice, Street Insider, Lebed.biz, INO.com Market Report, StockMarketWatch, QualityStocks, StockEgg, StreetInsider, TradersPro, Penny Invest, Hit and Run Candle Sticks, Momentum Traders, Zacks, HyperGrowthStock, HotOTC, Stock Rich, CoolPennyStocks, Marketbeat.com, PoliticsAndMyPortfolio, SmallCapNetwork, MarketBeat, CRWEFinance, BUYINS.NET, Bull Warrior Stocks, TraderPower and CRWEWallStreet reported beforehand on Sunesis Pharmaceuticals Inc. (NASDAQ: SNSS) (FRA: RYIS), now Viracta Therapeutics, Inc. (VIRX), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter. 

Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced the closing of its merger with Sunesis Pharmaceuticals, Inc. (previously trading on Nasdaq under "SNSS").

Sunesis Pharmaceuticals Inc. (NASDAQ: SNSS) (FRA: RYIS) was a biopharmaceutical firm engaged in the discovery, development and commercialization of therapeutics for inflammatory diseases and other diseases like solid and hematologic cancers.

The firm was founded on Feb. 10, 1998 and is based in South San Francisco, California. Sunesis Pharmaceuticals has a license agreement with Takeda Pharmaceutical Company TLD for the development and commercialization of PDK1 preclinical inhibitor as well as a collaboration agreement with Biogen Idec MA Inc. for the discovery, development and commercialization of small molecule BTK inhibitors.

Sunesis Pharmaceuticals raised capital, carried out clinical trials as well as internal research and development. This is in addition to out-licensing and in-licensing pharmaceutical technology and compounds through corporate collaborators.

The firm’s portfolio includes vecabrutinib, a BTK inhibitor which is currently in Phase 1b/2 of its clinical trial for the treatment of mantle cell lymphoma and chronic lymphocytic leukemia, among other B-cell malignancies. Its other candidate, SNS-510, is undergoing preclinical pharmacology studies for the treatment of hematologic and solid tumor malignancies. Other candidates include an anti-cancer quinolone derivative known as vosaroxin, which is indicated for the treatment of acute myeloid leukemia and TAK-580, which is currently undergoing a phase 1 clinical trial for pediatric low-grade glioma treatment.

Viracta Therapeutics, Inc. (VIRX), closed Thursday's trading session at $13.50, off by 27.50%, on 622,246 volume with 6,406 trades. The stock's 52-week low/high is $13.25/$18.24.

Troubadour Resources, Inc. (TROUF)

We reported earlier on Troubadour Resources, Inc. (TROUF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Troubadour Resources, Inc. engages in the acquisition, exploration, and evaluation of mineral properties in Canada. The Company’s focus is on copper in British Columbia. An experienced team of professionals with proven records of accomplishment as mine finders manage Troubadour Resources. The Company previously went by the name Grandore Resources, Inc. It changed its name to Troubadour Resources, Inc. in February of 2017. Incorporated in 2012, Troubadour Resources is headquartered in Vancouver, British Columbia. The Company lists on the OTC Markets and the TSXV.

Troubadour Resources has its Amarillo Copper Project. The Amarillo Property comprises 9 mineral claims encompassing 5,449 hectares. The Amarillo Project is positioned 10km to the south of the past producing Brenda Mine, and proximal to Highland Valley, Craigmont, and Copper Mountain mines. It is situated in the core of a major mining district.

The Amarillo Copper Property is strategically located close to major low cost copper producers. This gives it a distinct advantage for future development potential. The three targets are the Trench Anomaly, the Copper Rich Skarn Deposit, as well as the North Copper Anomaly.

The multi-element signature of the Amarillo Project area is consistent with a large multiphase mineralizing system. It is very similar to some of the neighbouring world-class mining operations. Prior completed drilling encountered mineralization and alteration indicative of an alkalic porphyry system.

Troubadour Resources announced this past October that it acquired by staking an additional 420 hectares (ha) of highly prospective ground contiguous to its Texas property located in the Greenwood Mining District. The Texas property now covers an area of 2,186 ha. The newly acquired Texas gold property diversifies Troubadour Resources’ commodity emphasis and complements the Company's copper project, the Amarillo property.

Recently, Troubadour Resources announced that it completed its Phase 1 exploration program on its 2,186-hectare Texas property positioned in the Greenwood Mining District of Southern British Columbia.

Troubadour Resources’ President, Mr. Geoff Schellenberg, stated, “The extent of mineralization and alteration observed in the host rock in proximity to the bonanza grade gold veins and at previously unsampled locations throughout the property has significantly increased the size potential of our exploration targets. Most of the historic and newly discovered showings are hosted in a similarly-altered granodiorite which until now remained untested and greatly overlooked."

Troubadour Resources, Inc. (TROUF), closed Thursday's trading session at $0.1233, up 82.6667%, on 131650 volume with 24 trades. The average volume for the last 3 months is 17,434 and the stock's 52-week low/high is $0.017249999/$0.137500002.

Acquired Sales Corp. (AQSP)

QualityStocks, SmallCapVoice and Money Morning reported  previously on Acquired Sales Corp. (AQSP), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Acquired Sales Corp. is a consolidator of companies making branded cannabinoid-infused products. These products include beverages, muscle/joint rubs, oils, crystals, tinctures, bath bombs, and isolate. Additionally, products include relief balms, elixirs, body washes, med sticks, lotions, vape pens and cartridges, shatter, and gummies. On February 24, 2020, the Company acquired 100 percent of fast growing and profitable Warrender Enterprise, Inc. d/b/a Lifted Made (formerly d/b/a Liquids), of Zion, Illinois. Acquired Sales has its corporate headquarters in Lake Forest, Illinois.

The Company believes in the value of cannabinoids (CBD, CBG, CBN, etc.). Furthermore, it owns 4.99 percent of CBD-infused beverage and products maker Ablis Holding Company, and of craft distillers Bendistillery, Inc. d/b/a Crater Lake Spirits and Bend Spirits, Inc., Bend, Oregon, that it purchased in 2019 for $1,896,200 in cash.

The Company’s House Brands include Lifted Made. This is the distinguished house of creative cannabis products targeting astute consumers who demand the highest quality products, speedy delivery systems, and lasting effects.

Moreover, House Brands include Levé-Pâte De Fruit. Levé is a cannabis-infused confectionary brand, centered around the highest quality vegan ingredients imported from France. Another House Brand is Urb-Finest Flower. Urb is an exclusive cannabis hemp flower brand. Urb is focused around supporting U.S. farmers, using rare hemp genetics (strains) paired with one-of-a-kind packaging.

Recently, Lifted Made announced its launch of the world’s first hemp-derived delta-8-THC nano-particle drops under Lifted Made’s flagship brand Urb Finest Flowers. Urb’s delta-8-THC nano drops are a flavored, water soluble tincture and beverage additive, and are federally legal. The nano drops sell in a one ounce bottle and contain 333 mg. of delta-8-THC and less than 0.3% delta-9-THC. At present, the product is available for purchase in three flavors: Go Grape, Let’s Mango, and Orange Dream.

Lifted Made also previously announced its launch of flavored nano CBD water enhancer packets under Lifted Made’s flagship brand Urb Finest Flowers. Urb’s nano CBD water enhancer packets are water soluble and are available in four flavors. These are mango, blue razz, watermelon, and lemon. Each packet contains roughly 10 mg. of CBD, and less than 0.3% delta-9-THC.

Acquired Sales Corp. (AQSP), closed Thursday's trading session at $6.25, up 19.0476%, on 8165 volume with 46 trades. The average volume for the last 3 months is 1,346 and the stock's 52-week low/high is $1.25/$7.00.

ChromaDex Corporation (CDXC)

RedChip, QualityStocks, SmallCap Network, Wall Street Resources, TraderPower, MarketBeat, StockMarketWatch, SmallCapVoice, FeedBlitz, Greenbackers, MarketClub Analysis, Marketbeat.com, PennyStockLocks.com, BUYINS.NET, InvestorPlace, Michael Stone, ResearchOTC, Stock Rocket Report, StockOodles, StockRockandRoll, Growing Stocks Reports, Investor Update, DreamTeamNetwork, Daily Stock Motion, OTC Markets Group, Penny Pick Insider, Penny Stocks VIP, Real Pennies, Red Chip, Research Driven Investor, SECFilings.com News, Stock News Now, Stock Traders Chat, Trades Of The Day and PennyStocks24 reported previously on ChromaDex Corporation (CDXC), and today we report on the Company, here at the QualityStocks Daily Newsletter. 

ChromaDex Corporation is a science-based integrated nutraceutical enterprise based in Los Angeles, California. Its dedication is to improving the way people age. The Company’s flagship ingredient, NIAGEN® nicotinamide riboside, sold directly to consumers as TRU NIAGEN®, is backed with clinical and scientific research, as well as extensive IP (Intellectual Property) protection. ChromaDex’s shares trade on the NasdaqCM.

The Company states that its TRU NIAGEN® is helping the world AGE BETTER®. ChromaDex’s scientists partner with foremost universities and research institutions worldwide to discover, develop, and create solutions to deliver the full potential of NAD and its impact on human health. ChromaDex has secured regulatory approval on its patent-protected Niagen® ingredient in Canada, Australia, and the European Union (EU).

Further to Chroma Dex’s ingredient technologies unit, it also has business units focused on natural product fine chemicals (called “phytochemicals”), chemistry, and analytical testing services. In addition, the Company has its product regulatory and safety consulting (known as Spherix Consulting). Thus, ChromaDex leverages its complementary business units to discover, acquire, develop, and commercialize patented and proprietary ingredient technologies. These address the dietary supplement, food, beverage, skin care, and pharmaceutical markets.

ChromaDex Chief Executive Officer, Mr. Rob Fried, recently said, "We achieved record net sales of $15.3 million in the second quarter of 2020 while maintaining our focus on the science, announcing our 200th research agreement and tenth published human trial on Niagen®. Business adjustments at the onset of the pandemic and continued marketing efficiencies allowed us to reach a financial goal of positive Adjusted EBITDA excluding total legal expenses."

ChromaDex also announced the 11th published human trial on its patented NAD-boosting nutrient Niagen®, further highlighting its potential to support cardiovascular health in humans. An NIH funded study by the Cardiology Division and Mitochondria & Metabolism Center at the University of Washington, published in The Journal of Clinical Investigation, found that Niagen supplementation decreased signs of inflammation, particularly inflammatory cytokines in vivo, in a small group of end-stage heart failure patients.

A second arm of the study, conducted ex vivo, found improved mitochondrial respiration and decreased inflammatory factor expressions in peripheral blood mononuclear cells (PBMCs) isolated from human subjects and treated with nicotinamide riboside.

ChromaDex Corporation (CDXC), closed Thursday's trading session at $18.74, up 92.4025%, on 119405224 volume with 520,870 trades. The average volume for the last 3 months is 523,511 and the stock's 52-week low/high is $2.50/$23.6599998.

Angkor Resources Corp. (ANKOF)

We reported previously on Angkor Resources Corp. (ANKOF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Angkor Resources Corp. is the first North American publicly-traded mineral and oil & gas exploration company in Cambodia. Its strategy centers on project generation and selecting strong partners to advance each of its numerous prospects towards a sustainable recurring revenue stream. The Company formerly went by the name Angkor Gold Corp. It changed its name to Angkor Resources Corp. in September of 2019. Incorporated in 2008, Angkor Resources is based in Sexsmith, Alberta.

Cambodia has a resource-rich geology, favorable mining policies, and accessible and mineable topography. Angkor has been working in the Kingdom of Cambodia since 2009. The Company has a large land package and a new oil and gas exploration license that includes 7,300 square kilometers of Cambodia.

Angkor Resources’ properties include Banlung (Okalla); Andong Meas; Oyadao; Oyadao South (Halo); and Koan Nheak. The Banlung property includes two main prospects. These are Okalla West and Okalla East with gold mineralization associated with an alkaline intrusive complex.

The Oyadao South License contains several prospects, including the Halo Prospect. The Koan Nheak Licence is 189 km2. It lies immediately south of the town of the same name in the northeast of Mondulkiri Province.

Andong Meas is positioned 50 kilometers east of the provincial capital Banlung along a paved highway. Oyadao is a 222 km2 license area close to the Vietnam border. The Oyadao South License is about 247 sq. km. This license was renewed in 2017 for 3 years with extensions for an additional 4 years.

Angkor Resources’ Chief Executive Officer, Mr. Stephen Burega, previously reported on the recently completed mapping and sampling program on the Company’s 100 percent owned Andong Meas property. Highlights include multiple grab samples with gold from 3.08 to 55.4 g/t grams of gold per tonne. A significant gold target was identified from samples collected over a north to south distance of greater than 600 meters. In addition, there is evidence of multiple mineralized epithermal quartz veins and skarn type alteration across the license. This includes the Wild Boar and Wild Monkey prospects.

Mr. Burega also noted at the time the closing of the non-brokered private placement of units announced on May 29, 2020, raising a total of $1,800,000.00. Angkor’s intention is to use the money raised from the issuance of the Units to fund continuing exploration and drilling at its Andong Meas license; operating costs, and for general working capital. Some of the proceeds will be used to pay off existing debts to creditors.

Mr. Burega stated, “Today’s marketplace is challenging but we continue to explore, so an oversubscribed non-brokered placement puts funds in place to move our Andong Meas gold license forward. And to have Palisades Goldcorp come in as a new significant investor shows the prospectivity of our property portfolio and Cambodia’s geological potential.”

Angkor Resources Corp. (ANKOF), closed Thursday's trading session at $0.0482, up 19.0123%, on 67000 volume with 2 trades. The average volume for the last 3 months is 13,628 and the stock's 52-week low/high is $0.01875/$0.083999998.

Basic Energy Services, Inc. (BASX)

QualityStocks and StreetInsider reported previously on Basic Energy Services, Inc. (BASX), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter. 

Basic Energy Services, Inc. provides well site services to oil and natural gas drilling and producing companies in the USA. The Company supports six geographic markets conducting operations in the Texas Gulf Coast region, the Central region, the Permian Basin of West Texas, California, and the Rocky Mountains. Its services include Well Servicing, Midstream Services, Water Logistics, Pumping Services, and Rental/Fishing Tools. The Company provides its services to a varied group of more than 2,000 oil and gas companies. Basic Energy Services is based in Fort Worth, Texas. The Company’s shares trade on the OTC Markets Group’s OTCQX.

Basic Energy Services’ operations are centered in liquids-rich basins that have historically exhibited strong drilling and production economics in recent years with a considerable presence in the Permian Basin, Powder River Basin, and the Bakken, Eagle Ford, and Denver-Julesburg shales. The Company's Well Servicing operations take advantage of a contemporary fleet of high spec workover rigs, 24 hour rig packages and 700 rig series, matched to the needs of the local markets.

Basic Energy Services’ Pumping Services include Hydraulic Fracturing; Cementing; Acidizing; Nitrogen; Coil Tubing; Water Solution Services; and Frac Stacs. Additionally, its Midstream Services is now Agua Libre Midstream. Moreover, the Company has its network of 24 Rental & Fishing Tools facilities. It offers a wide-ranging line-up of rental tools that range from the smallest to the largest, as well as an extensive inventory of fishing tools.

The Company’s Water Logistics operations provides oilfield fluid supply, transportation, storage, and disposal services required in workover, completion, and remedial projects and also in daily producing well operations. Its high spec well servicing rigs perform reliable services to maintain and improve production throughout the productive life of the well.

Recently, Basic Energy Services announced that it acquired the production operations from NexTier (NYSE:NEX) for a consideration of about $94 million. The NexTier production operations, known as C&J Well Services, is the third largest rig servicing provider in the USA. C&J Well Services has a leading footprint in the State of California and comes with a blue-chip customer base.

Basic Energy Services, Inc. (BASX), closed Thursday's trading session at $0.36, up 26.3158%, on 499341 volume with 190 trades. The average volume for the last 3 months is 202,225 and the stock's 52-week low/high is $0.065099999/$0.448000013.

Jacksam Corporation (JKSM)

QualityStocks and CFN Media Group reported beforehand on Jacksam Corporation (JKSM), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Jacksam Corporation is a workflow automation company centered on developing machinery and equipment solutions for the cannabis and CBD (cannabidiol) industry. The Company designs and markets proprietary automated vape, POD and cartridge filling/capping equipment for the cannabis industry. It serves the medical cannabis, hemp, and CBD segments of the e-cigarette and vaporizer markets with its oil vaporizer focused products. Jacksam is based in Rancho Santa Margarita, California. The Company lists on the OTC Markets’ OTCQB.

Jacksam’s automated equipment is designed and built in the USA. It carries the only full UL certification in the U.S. Using Jacksam/Convectium's automated equipment, its customers increase output by up to 60 times over hand filling. Jacksam/Convectium is focused on helping its customers automate their workflow and get custom branded products onto dispensary shelves fast. More than 100 companies, including many dominant brands in the space, rely on Jacksam/Convectium for automation of their filling operations.

The Company has adopted an “open source” business model enabling the majority of cannabis and CBD oil producers to benefit from its filling and capping equipment. Jacksam (shifting away from a closed system approach) has made its vape, POD and cartridge trays and equipment compatible with components produced by most of the top international manufacturers.

Recently, Jacksam announced that The Stock Day Podcast welcomed Jacksam Corporation. The President and Chief Executive Officer of the Company, Mr. Mark Adams, joined Stock Day host Everett Jolly. Jolly began the interview by commenting on Jacksam's partnership with Jupiter Research, LLC, and what it means for their future.

Mr. Adams said, "Jupiter is by far the leading C-Cell technology company selling in the United States and abroad. They bring a quality and research and development technology aspect to a partnership that we really value."

Jacksam Corporation (JKSM), closed Thursday's trading session at $0.2297, up 43.5625%, on 125129 volume with 34 trades. The average volume for the last 3 months is 49,322 and the stock's 52-week low/high is $0.05/$0.990000009.

Iconic Brands, Inc. (ICNB)

Bloomfield Investment Club, SmallCapVoice, AwesomeStocks, QualityStocks, DSR News, OTC Picks, 24-7 Stock Alert, Penny Invest, Penny Stock Hub, Global Equity Report, Nebula Stocks, CoolPennyStocks, OTCPicks, PHUB News, BestDamnPennyStocks, TheNextBigTrade, Broad Street, HotOTC, Light Speed Stocks, Beacon Equity Research, MicroStockProfit, Monster Stock Alerts, AlphaTrade, Damn Good Penny Picks, PennyStockRumors.net, The Observer, StockEgg, Stock Rich, smartOTC, Small Cap Firm, OTCBB Journal, PennyTrader Publisher, Morning Stock Picks, Penny Stock Professor, Penny Stock Newsletter, Penny Stock Explosion, Penny Picks, TopPennyStockMovers, OtcWizard and PREPUMP STOCKS reported beforehand on Iconic Brands, Inc. (ICNB), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Iconic Brands, Inc. is a beverage company listed on the OTC Markets Group’s OTCQB. The Company’s expertise is developing, from inception to completion, alcoholic beverages for itself and third parties. It markets and places products into national distribution via long standing industry relationships. Iconic Brands offers wine and distilled alcoholic beverages, and also liquor based products infused with hemp and CBD. The Company is headquartered in Amityville, New York.

Iconic Brands is a leader in Celebrity and Private Label beverages. It obtains first-rate and innovative products from around the world and brands its products with globally recognized celebrities and corporate icons. The Company’s corporate mission is to be the industry leader in brand development, marketing, and sales of the highest quality alcoholic beverages.

Iconic Brands is under contract with United Spirits - a federally-licensed importer and distributor of alcoholic beverages. In addition, the Company is under contract with Mr. Dan Kay, who maintains a New York State warehousing license for alcoholic beverages.

Regarding Services, Iconic Brands’ takes a customer’s product idea from concept to completion. This includes everything from sourcing, flavor profiles, packaging, design, marketing and distribution. Iconic an also align a customer’s brand with select celebrity endorsement. Iconic markets its products under the Bivi, Bellissima, Bella, and Romano brand names.

Recently, Iconic Brands announced it entered into a Letter of Intent (LOI) to acquire recently formed Green Grow Farms, Inc. Green Grow Farms partners directly with farmers to transition their crops to hemp for the purpose of extracting Cannabidiol (CBD Isolate/Oil). It provides full support services and logistics to take product from seed to sale.

Iconic Brands also announced that Green Grow Farms secured a processor and material supplier agreement with one of the largest vertical Hemp processors in the world. The agreement is for an initial 2-year term. It allows for a minimum of 2 million pounds of biomass to be processed to CBD isolate, and sold under a revenue sharing agreement. With average CBD percentage and processing efficiency rates from Green Grow’s farming operations, two million pounds should process into roughly 40,000 kilograms of CBD Isolate.

Additionally, Iconic Brands, in conjunction with its Licensed Partner, United Spirits, announced the introduction of Hooters Spirits, with the official debut at this year’s WSWA Conference. Hooters Spirits is a private label brand for Hooters of America, the iconic restaurant chain. The product portfolio comprises Hooters Vodka, Hooters Gin, Hooters Rum, Hooters Tequila, Hooters American Whiskey and Hooters Shooter, a cinnamon flavored whiskey.

Iconic Brands, Inc. (ICNB), closed Thursday's trading session at $0.48, up 28.00%, on 81148 volume with 25 trades. The average volume for the last 3 months is 73,312 and the stock's 52-week low/high is $0.090999998/$0.898000001.

Workhorse Group, Inc. (WKHS)

Green Car Stocks, MarketClub Analysis, InvestorPlace, Schaeffer's, Kiplinger Today, StockMarketWatch, MarketBeat, QualityStocks, StreetInsider, TradersPro, Trades Of The Day, TraderPower, The Street, TopPennyStockMovers, Wealth Insider Alert, StocksEarning, The Online Investor, Cabot Wealth, Daily Trade Alert, Marketbeat.com, Jason Bond, PoliticsAndMyPortfolio, BUYINS.NET, StockOodles, Zacks, The Best Newsletters, Profitable Trader Authority, The Wealth Report, Wealth Daily, Energy and Capital, Early Bird, Daily Market Beat, Stock Beast and InvestorsUnderground are reporting on Workhorse Group, Inc. (WKHS), here at the QualityStocks Daily Newsletter.

Workhorse Group, Inc. is a technology company centered on providing sustainable and cost-effective electric mobility solutions to the commercial electric transportation sector. The Company designs and builds high performance battery-electric vehicles including trucks and aircraft. The design of all Workhorse vehicles is to make the movement of people and goods more efficient and less harmful to the environment. An American original equipment manufacturer (OEM), Workhorse Group is based in Loveland, Ohio.

The Company designs and produces battery-electric power trains in its 50,000 sq. ft. facility in Loveland for its new Workhorse chassis. Its approach to building its battery electric power trains uses proven, automotive-grade, mass-produced parts together with its custom designed, proprietary control software.

Workhorse Group also develops cloud-based, real-time telematics performance monitoring systems. These systems are totally integrated with its vehicles. They enable fleet operators to optimize energy and route efficiency. The Company is a top manufacturer of medium-duty electric step vans in America targeting commercial fleets. Workhorse Group is the only OEM building electrified medium-duty vehicles in America.

The Company is developing the Workhorse W-15, the U.S.’ first light-duty pickup truck with electric powertrain targeted at commercial fleets. Target customers include delivery fleets, utility companies, telecommunications companies, municipalities and more. Workhorse Group has its N-GEN Electric Delivery Van; the W-15 electric pickup truck with extended range; the E-Gen Step Van; the SureFly™ Helicopter; the HorseFly™ Autonomous Drone Delivery System; and the METRON™ Telematics and Asset Tracking Software.

The SureFly is classified as a personal helicopter/eVTOL aircraft. The Company has received FAA approval to test the copter. However, it is still trying to secure approval to sell it. Mr. Steve Burns, Workhorse Group Chief Executive Officer, said the Company is "six months into a two-year journey" to get the product approved and sold.

In addition, Workhorse Group is working with Duke Energy Corp. (NYSE: DUK) on a battery leasing program. This program would provide Duke Energy customers a cost-competitive product alternative.

As part of this relationship, signed in 2018, Duke Energy agreed to buy 615,000 Panasonic battery cells from Workhorse Group for $1.3 million. Duke’s plan is to explore further development of eFleet solutions to Workhorse customers that may include single-point management and financing of all the Behind the Meter (BTM) infrastructure required to support depot wide electrification, vehicle/battery leasing, as well as distributed energy resources.

Workhorse Group, Inc. (WKHS), closed Thursday's trading session at $18.87, up 24.7191%, on 81619824 volume with 441,570 trades. The average volume for the last 3 months is 17,453,983 and the stock's 52-week low/high is $1.31500005/$42.959999.

Mundoro Capital Inc. (TSX.V: MUN) (OTCQB: MUNMF)

We reported previously on Mundoro Capital Inc. (MUNMF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Mundoro Capital Inc. (TSX.V: MUN) (OTCQB: MUNMF) is a Canadian-listed royalty generator company with a portfolio of projects focused on base and precious metals that generate royalties and near-term mineral revenue. To drive value for shareholders, Mundoro has generated a portfolio of mineral projects primarily focused on copper and gold in Serbia and Bulgaria. Value generated from the company’s mineral properties is through near term revenues from various forms of payments from partners and long term through the generated royalties. For more information, visit the company’s website at www.mundoro.com.

To watch the presentation, visit https://ibn.fm/NobleCon17Registration

To view IBN’s virtual coverage of Noble Capital Markets’ 17th Annual Small & Microcap Investor Conference, visit https://ibn.fm/NobleCon17

Mundoro Capital Inc. (MUNMF), closed Thursday's trading session at $0.2016, up 22.1818%, on 124900 volume with 18 trades. The average volume for the last 3 months is 13,848 and the stock's 52-week low/high is $0.058159999/$0.206688001.

Deutsche Bank AG (NYSE: DB)

The Street, Schaeffer's, InvestorPlace, MarketClub Analysis, Money Morning, StreetInsider, Money and Markets, Kiplinger Today, Daily Trade Alert, StocksEarning, StreetAuthority Daily, Investopedia, TopStockAnalysts, SmarTrend Newsletters, MarketBeat, Zacks, Trades Of The Day, Louis Navellier, Daily Wealth, Market Authority, ProfitableTrading, Barchart, Uncommon Wisdom, Marketbeat.com, SureMoney, Daily Profit, Investment U, Shah's Insights & Indictments, 24/7 Trader, INO.com Market Report, CustomerService, Investing Daily, BUYINS.NET, The Street Report, InvestorGuide, QualityStocks, CNBC Breaking News, Trading Markets, Profit Confidential, The Growth Stock Wire, StrategicTechInvestor, Market Intelligence Center Alert, Street Insider, Dynamic Wealth Report, AllPennyStocks, Wealth Daily, Capital & Conflict, Daily Markets, StockMarketWatch, OnTheMar, Wyatt Investment Research, PennyPickGains, Wall Street Greek, Top Pros' Top Picks, SmallCapVoice, Wall Street Daily and The Online Investor reported previously on Deutsche Bank AG (DB), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Deutsche Bank AG (NYSE:DB) traded today at a new 52-week high of $13.19. So far today approximately 4.3 million shares have been exchanged, as compared to an average 30-day volume of 2.9 million shares.

Deutsche Bank AG (NYSE:DB) is currently priced 8.8% above its average consensus analyst price target of $11.89.

In July 2019, Deutsche Bank announced another restructuring plan hoping to revitalize revenue, reduce costs, and return to profitability. The largest moving pieces of the new plan is the full exit of global equity sales & trading, the scaling back of its fixed income business, as well as 18,000 FTE reductions until 2022. The remaining core business segments include private banking, corporate banking, asset management, and investment banking.

Deutsche Bank AG share prices have moved between a 52-week high of $13.19 and a 52-week low of $4.99 and are now trading 161% above that low price at $13.04 per share.

Deutsche Bank AG (DB), closed Thursday's trading session at $12.75, up 2.492%, on 8832199 volume with 22,690 trades. The average volume for the last 3 months is 2,753,536 and the stock's 52-week low/high is $4.98999977/$13.1899995.

The QualityStocks Company Corner

Healthtech Solutions Inc. (OTC: HLTT)

The QualityStocks Daily Newsletter would like to spotlight Healthtech Solutions Inc. (OTC: HLTT).

Healthtech Solutions (OTC: HLTT), through its recent acquisition of Mediscan Inc., is looking to bring significant value to the U.S. medical imaging market, which reached $134 billion in 2020 (https://ibn.fm/qB40D). Mediscan, a cloud-based technology used in ultrasounds, reconstructs the traditional analog two-dimensional (“2D”) grayscale visual image into a high-definition, three-dimensional (“3D”) digital format. To view the full article, visit https://ibn.fm/Krq3r

Healthtech Solutions Inc. (OTC: HLTT), through its Mediscan Inc. subsidiary, created a cloud-based software for ultrasound technology that reconstructs the analog two-dimensional grayscale visual image into a digital three-dimensional, high-definition quantifiable format.

The Mediscan software application dramatically increases the medical professional’s ability to use existing ultrasound devices at the point of care to derive meaningful data-driven clinical evaluations of a patient’s pathology or trauma, facilitate support for treatment options, monitor the patient’s ongoing progress or regress, and document compliance with required protocols and procedures. The Mediscan application also integrates with all popular EMR systems.

Healthtech Solutions Inc. acquired all of Mediscan’s capital stock in a reverse acquisition transaction on November 13, 2020. On November 23, 2020, the shareholders of Healthtech Solutions Inc. consented to a resolution changing its name to Healthtech Solutions Inc.

The company’s operational focus for the immediate future will be on Mediscan’s continuing research and development of imaging, development of other medical solutions, and making strategic investments.

Mediscan Technology

Mediscan software transforms an ultrasound analog 2D grayscale image into a digital 3D HD format. When paired with a portable ultrasound machine, the software application can enable these detailed and quantifiable scans by on-the-scene medical professionals, such primary care physicians, specialists and technical support staff, as well as sports trainers, emergency medical services (EMS) personnel, and technicians in isolation wards and emergency rooms.

Once an image has been captured in 2D, it is converted using a cloud-based software application process – a process that takes approximately one minute. The completed 3D image is viewed on the medical professional’s computer monitor, pad or smartphone at the point of service. This technique can generate 3D medical images of different organs, such as the heart, lungs, tendons, skin and nerves.

This cloud-based software application for ultrasound devices is easy to use anywhere there is an internet connection. The application provides the convenience of point of care ultrasound with the image quality of CT or X-ray and the safety of very expensive MRI technology. For patients, it provides a convenient and comfortable medical experience.

Mediscan has filed two patent applications with the United States Patent and Trademark Office, both for a System Method, Apparatus, and Computer Program Product for Ultrasonic Clinical Decision Support (https://ibn.fm/lpImS).

The technology will initially be available as medical software-as-a-service (SaaS), resulting in cost-efficiency. The SaaS model eliminates the customer’s need for external hardware and software solutions, as well as technical maintenance. The SaaS model is already widely used in the health care industry, most notably for clinical information systems and supply chain management, revenue cycle management and billing. Benefits include increased patient and physician satisfaction, lower operational costs, better workflows and more. Per company data, the Mediscan system is fast and efficient, which could generate a significant cost reduction.

Health and Wellness Applications

Mediscan’s technology has shown success in musculoskeletal (MSK), lung and cardiac imaging, enabling rapid pathology evaluation. Scanning the lung and or the MSK sub-system, the application directly images the target area, saves it as a reference, and then compares it to previous images, helping to determine if the patient is progressing or regressing.

The cardiac application combines imaging with a therapy system that detects and classifies cardiac myopathy conditions via an “entrainment” process similar to that used in treating tachycardia. This application also features a comparison function where the latest imagery is interpreted against previous vetted cardiac images to detect progression or regression.

Mediscan’s technology can also be utilized on the wellness market for diagnostics and support in a wide range of situations, such as sports injuries, physical therapy and dermatological indications.

COVID-19 Applications

COVID-19 causes complications with patients’ cardiovascular and pulmonary systems. Mediscan’s technology could help meet the growing need for advanced diagnostic and monitoring imaging at the point of care.

Portable ultrasounds equipped with Mediscan’s application are a flexible and easy-to-use solution for health care providers to evaluate, triage and diagnose COVID-19 effects on contagious patients in isolation where MRI, CT or PET Scans are not accessible. With this technology, health care providers can easily detect lung lesions or heart muscle shredding, which often appear in patients with COVID-19.

Diagnostic Imaging Market Outlook

With the increasing demand for early diagnosis and a widening scope of clinical applications, any promising technological advancements in the field constitute a significant investment opportunity. The global market is also being driven by technological advances in the diagnostic imaging industry.

As standard ultrasound 2D greyscale images are generally the norm, and 3D imaging typically requires the use of CT, PET, MRI or X-ray technology, Mediscan’s application could have a dramatic impact on the medical imaging industry, meeting the need for imaging equipment and devices that can generate human anatomy data in 3D.

The global market for diagnostic imaging was estimated at approximately $100 billion in 2016 (https://ibn.fm/xtInK) and was expected to grow steadily, creating a promising opportunity for Mediscan to distribute its technology and achieve its mission as a developer and distributor of medical imaging solutions designed for both long-term care and acute and emergency medical services.

Management Team

David Rubin is the Chairman and CEO of Healthtech Solutions Inc. Mr. Rubin has been in the financial services business for over 20 years. Concurrently, he is also the CEO of Capital Stack LLC and CEO of eProdigy Financial LLC. Rubin attended Kingsborough Community College from 1985 to 1988.

Manuel Iglesias is the President and a Director of Healthtech Solutions Inc. Mr. Iglesias has practiced law since 1980, specializing in business law, merger and acquisitions, securities and health care. Mr. Iglesias served as President, CEO and a board member of Hygea Holdings Corp., which provided primary care medical services throughout Florida and Georgia. He served as the National Chairman of the Republican National Lawyers Association in 2019 and 2020. Mr. Igleisias was awarded his MBA degree from the University of Chicago in 1981, a Juris Doctorate from the University of Chicago in 1979, and a BS in Foreign Service from Georgetown University in 1976.

Denis Kleinfeld is a Director of Healthtech Solutions Inc. and General Counsel and a Director of Mediscan Inc. Mr. Kleinfeld has extensive experience in business planning and regulatory compliance. Mr. Kleinfeld is a renowned expert in international tax and estate planning law. Kleinfeld received his Juris Doctorate from the Loyola University of Chicago School of Law in 1970.

Richard F. Parker is the Chief Research Officer of Mediscan Inc. He developed the technology that is the foundation of Mediscan’s business plan. Before he joined Mediscan, Mr. Parker was employed as an engineer and business executive for 37 years. Previously, he was President and Chief Technology Officer of CytoWave LLC. Mr. Parker was awarded a patent for technology that supported a Method and Apparatus for Generating a Therapeutic Magnetic Waveform. During the past 10 years, Mr. Parker has published 14 papers and made numerous presentations focused on magnetic imaging and treatment of sports and equine injuries. He obtained his MSEE degree from the Georgia Institute of Technology in 1971.

Healthtech Solutions Inc. (HLTT), closed Thursday's trading session at $0.27, off by 32.50%, on 76735 volume with 25 trades. The average volume for the last 3 months is 27,783 and the stock's 52-week low/high is $0.024/$0.59890002.

Recent News

XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT)

The QualityStocks Daily Newsletter would like to spotlight XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT).

XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) was featured today in a publication from PsychedelicNewsWire, examining how, last week, legislators in Massachusetts introduced initiatives that may help end the war on drugs in the state. One measure would establish a task force whose focus will be to study fungi and plant-based psychedelics, its objective being to regulate and legalize these substances. The  second other proposal would do away with criminal penalties for drug possession. Also today, the company was featured in the 420 with CNW by CannabisNewsWire. Elon University conducted an online survey earlier this year, between Jan. 29 and Jan. 31, 2021. The university recently released the results of the statewide poll, which asked residents of North Carolina to share opinions on legalizing cannabis for various purposes.

XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) is a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities. This includes products that are being readied for commercialization within the coming weeks, such as a rapid COVID-19 PCR test kit that reduces turnaround times to less than 30 minutes.

The company has research and development operations in North America and Europe and an operational focus in Germany. Its regulatory approval and commercialization focus is currently on products for the European market.

XPhyto was founded in 2017 and is headquartered in Vancouver, British Columbia.

Business Strategy & Milestones for 2021

On January 18, 2021, XPhyto issued a news release detailing its business strategy for the coming year. The company noted that it is “on the cusp of transformational change as product development programs advance from the laboratory to the clinic.” In addition to continuing to leverage its scientific expertise and operations in North America and Europe for product development and optimization, XPhyto intends to pursue growth through the commercialization of existing products and adherence to a focused investment strategy targeting impact-driven innovation with “the potential for extreme value creation.”

In particular, XPhyto is well positioned to execute on opportunities across its current business divisions, including:

  • Commercialization of infectious disease diagnostics
  • Clinical validation of transdermal and sublingual drug formulations
  • Continued investment and development in psychedelic medicine

“2020 was a very productive year for XPhyto. We made significant progress in all areas of our business,” Hugh Rogers, CEO & Director of XPhyto, stated in the update. “We have ambitious milestones for 2021 with multiple product launches on the horizon, multiple clinical drug programs underway, and an aggressive commitment to psychedelic medicine. I am extremely confident that our team can execute on the company’s business plan for 2021.”

Infectious Disease Diagnostics

XPhyto’s lead diagnostic product, secured through an exclusive global commercialization agreement with 3a-diagnostics GmbH (“3a”), is a rapid and highly portable PCR diagnostic test. Notably, PCR testing “has emerged as the only internationally recognized standard for COVID-19 testing” and is expected to play a key role in facilitating the recovery of the domestic and international travel industries, among others.

Successful validation of the PCR system was achieved in Q4 2020, and XPhyto has expressed confidence that it will achieve European commercial (CE-IVD) approval in Q1 2021. In preparation for this milestone and an anticipated Q1 product launch, the company is currently in discussion with manufacturing and distribution partners in Europe and the Middle East.

In addition to COVID-19 products, XPhyto and partner 3a are developing and commercializing a portfolio of low-cost oral biosensors. The company’s lead biosensor product is an oral health screening test for the detection of peri-implantitis for which XPhyto is targeting a late 2021 European commercial approval.

XPhyto does not make any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 pandemic.

Drug Formulation & Delivery

In 2020, XPhyto’s German subsidiary, Vektor Pharma TF GmbH (“Vektor”), reported significant advancement in four therapeutic programs targeting neurological indications with significant market demand. Vektor also successfully developed a sublingual drug formulation on contract for a major generic drug manufacturer and distributor.

XPhyto will look to build on this progress in 2021, with plans to complete human pilot studies evaluating its four lead therapeutic products:

  • Rotigotine transdermal patch for Parkinson’s disease
  • CBD oral/sublingual strip for treatment resistant epilepsy
  • THC oral/sublingual strip for anorexia/nausea
  • CBD:THC (1:1) oral/sublingual strip for multiple sclerosis associated spasticity

Per its 2021 business update, the company is currently in “ongoing discussions with multiple potential commercial partners, licensors and distributors and will be reviewing monetization opportunities on a continued basis.”

Psychedelic Medicine

Psychedelic compounds are a highly promising new class of active pharmaceutical ingredient (“API”) demonstrating strong potential for a variety of mental health conditions. XPhyto is positioned to capitalize on this promise through two strategic initiatives:

  • An agreement for the development of industrial scale biotechnology processes for the production of psilocybin
  • An agreement for R&D related to multiple psychedelic compounds, including psilocybin, mescaline, LSD, MDMA and DMT, among others

XPhyto intends to advance and expand its programs focused on the industrial scale production of psychedelic API in 2021. The company also plans to launch new programs for the development of psychedelic drug formulations, with a focus on sublingual and transdermal therapeutics and the integration of these products into established clinical programs relating to mental health indications.

Management Team

Hugh Rogers is the CEO and Director of XPhyto Therapeutics Corp. He is an entrepreneur and lawyer with private and public start-up company experience in various industries and operational roles. His recent advisory work has focused on public listings and corporate restructuring. This restructuring has occurred in the life science (cell therapy and medical device) and natural resources (natural gas co-gen and conventional oil) industries. Mr. Rogers holds a bachelor’s degree in Cellular Biology and Genetics and a law degree. He is a member in good standing of the Law Society of British Colombia.

Christopher Ross is the CFO of XPhyto. He is a professional accountant with broad financial experience across numerous industries, including forestry, distribution, construction, mining and multi-family real estate. He has provided advisory services to private and public companies in the areas of financial accounting, strategic analysis, audit and taxation. Mr. Ross holds a bachelor’s degree in commerce. He is a member in good standing with the Chartered Professional Accountants Association of British Columbia.

Wolfgang Probst serves as Director of XPhyto and Managing Director of BUNKER Pflanzenextrakte GmbH. He is a seasoned management and financial consultant based in Bavaria, Germany. He has consulting experience as branch head working with private clients and corporations of high net worth. In 2017, Mr. Probst assumed the CFO role of BUNKER and continues to play a key role in its operational and financial development.

Professor Dr. Raimar Löbenberg serves as Director of XPhyto. He holds a Bachelor of Science in pharmacy from Johannes Gutenberg-University and a Ph.D. in pharmaceutics from the Johann Wolfgang Goethe-University. He is the co-founder of RS Therapeutics Inc., which concentrates on foam-based topical drug delivery systems.

Professor Dr. Thomas Beckert is the Founder and Managing Director of Vektor Pharma TF GmbH. His expertise includes the formulation and machine development of transdermal therapeutic systems and ODFs. Professor Beckert holds a Bachelor of Science in pharmacy from the University of Freiburg and a Ph.D. in pharmacy and economics from the University of Tubingen.

XPhyto Therapeutics Corp. (OTCQB: XPHYF), closed Thursday's trading session at $2.57, up 1.581%, on 180943 volume with 574 trades. The average volume for the last 3 months is 61,812 and the stock's 52-week low/high is $1.3125/$3.0999999.

Recent News

Plus Products Inc. (CSE: PLUS) (OTC: PLPRF)

The QualityStocks Daily Newsletter would like to spotlight Plus Products Inc. (CSE: PLUS) (OTC: PLPRF).

Plus Products (CSE: PLUS) (OTCQX: PLPRF), a cannabis and hemp-branded products company in the United States, has announced that holders of the company’s 8% unsecured convertible debentures approved several amendments and resolutions. The approval came via signed instruments in writing in the form of proxy. The announcement noted that the amendments have been validly approved. Because the approval has been obtained via proxy, the debentureholder meeting scheduled for today has been cancelled. To view the full press release, visit http://ibn.fm/v4znx

Plus Products Inc. (CSE: PLUS) (OTC: PLPRF) is a branded cannabis-infused products manufacturer of edibles created to support a healthy and active lifestyle. Headquartered in San Mateo, California, PLUS™ concentrates on producing edibles using extracts to ensure compliant, dosable and delicious products that provide a consistent cannabis experience.

First introduced to the market in 2015 to rave reviews, PLUS™ is now one of the top best-selling edible brands in California. PLUS™ operates through a wholly owned subsidiary, Carberry, and has four cannabis-infused gummy candy SKUs (in addition to limited edition SKUs), that are currently sold in over 200 licensed dispensaries and delivery services. All products under the PLUS™ brand are produced in the company’s 12,000-square-foot food-safe cannabis manufacturing facility in Adelanto, California.

PLUS Products shares are currently listed on the Canadian Securities Exchange. PLUS™ raised CAD$20 million through the offering, for which the lead underwriters were PI Financial and Canaccord Genuity. The company intends to use a portion of the IPO proceeds to fund rapid product capacity expansion, factory automation, working capital and new product development.

Operating in the largest adult-use recreational market in the U.S., PLUS Products holds a temporary manufacturing license in California and was one of the first brands to bring fully compliant products to the legal market. California legalized adult use recreational sales on Jan. 1, 2018, and industry analysts expect edible sales there will continue to amass enviable revenues. According to BDS Analytics, edibles made up 18 percent of marijuana retail sales in February 2018 across licensed retailers in California, with PLUS™ products ranking in the Top 10 of edible brands by retail dollar sales.

During the first half of 2018, PLUS Products generated US$2.45 million in sales, a marked improvement over 2017’s US$1.07 million in sales. The company’s established cannabis products are not only compliant with state laws, they are proving to be extremely popular with consumers. Among the PLUS™ product brands are:

  • Blackberry & Lemon RESTORE, an infusion of carefully dosed cannabis with a 9:1 THC to CBD per gummy.
  • Sour Watermelon UPLIFT, a low-calorie gummy crafted from carefully dosed cannabis with an infusion of 5mg THC per gummy.
  • Pineapple & Coconut CBD RELIEF, a tropical flavor gummy made from pure cannabis-derived CBD that is low-calorie, gluten-free and made with kosher ingredients.
  • Sour Blueberry CREATE, a low-calorie gummy infused with hybrid flower containing 5 mg THC.
  • Limited Edition Rose & Vanilla, available at select locations during Winter 2018, these gummies are crafted with 60 mg THC/30 mg CBD per tin.
  • Limited Edition RAINBOW SORBET gummies was created to celebrate Pride during Spring 2018 with a portion of each purchase donated to The Trevor Project, a confidential suicide hotline for LGBT youth.

“We are extremely proud of the products PLUS has brought to market,” remarked Jake Heimark, CEO and cofounder in a statement. “We’ve quickly grown into one of the leading edible brands in California. With the proceeds of this round, we will continue to further our mission: to make cannabis safe and approachable for all types of consumers.”

The PLUS™ team believes that everyone deserves access to consistent, dosable and delicious cannabis products and strives to make that happen. Producing the best infused products at scale requires thoughtful collaboration among experts in many fields. At PLUS™, our team is comprised of Chefs, Chemists, Food Manufacturing Experts, Engineers, Machinists, Visionaries, Creatives, Strategists and others.

Plus Products Inc. (PLPRF), closed Thursday's trading session at $0.88, up 16.3098%, on 260942 volume with 155 trades. The average volume for the last 3 months is 186,978 and the stock's 52-week low/high is $0.279000014/$1.14999997.

Recent News

Sanwire Corp. (SNWR)

The QualityStocks Daily Newsletter would like to spotlight Sanwire Corp. (SNWR).

Sanwire (OTC: SNWR), a marketing and distribution SaaS (“SaaS”) company with a focus on technologies for the entertainment industry, announced that its wholly owned subsidiary, Intercept Music, has released a new playlist curation arm. Called Notes Worthy Music, the service creates Spotify playlists in the top music genres. These playlists will include some of the most popular titles within each genre; in addition, the music compilation will also feature genre music from Intercept Music artists. To view the full press release, visit http://ibn.fm/z7af9

Sanwire Corp. (SNWR) is a diversified company currently focused on technologies for the music industry. The company specializes in locating unique opportunities in fragmented markets and implementing its aggregated technologies to consolidate distinct services into unified platforms of delivery. Sanwire is currently focusing these efforts on advanced entertainment technologies.

Founded in 1997 and based out of Las Vegas, Nevada, Sanwire has operated and sold several subsidiaries as it has worked in various industry segments, including Sanwire Software Inc., Bullmoose Mines Ltd. and Squeeze Report Inc. Currently, there are two new holdings that were added to the company’s portfolio through two recent acquisitions, including Intercept Music Inc. in March 2020 and the Art is War Record Label in June 2020.

Intercept Music Inc. – Artist-Focused Services

Intercept Music Inc. is an entertainment technology company offering a unique suite of artist-focused services that are specifically designed to meet the needs of recording artists. Intercept’s proprietary online platform is dedicated to helping millions of global independent artists effectively promote their music and distribute it worldwide to hundreds of digital stores and every major streaming platform, including Spotify, Apple Music, Amazon Music, Pandora and Google Music.

With Intercept Music, recording artists have all the tools needed to market, promote and sell their music online and through social media. Comprehensive reporting allows artists to track the fan response to their releases, all the way down to individual music tracks.

There are three foundations of Intercept Music’s product offering:

  • Its music distribution platform that is well augmented via the company’s partnership with InGrooves, a wholly owned subsidiary of Universal Music, which is arguably one of the largest music companies in the world.
  • Its social media system, which is tailored to work the way artists use social media to promote their music and engage with their fans. The scheduling system integrates artists’ profiles across multiple social networking sites (Facebook, Twitter, Instagram and YouTube) to facilitate new audience sampling, fan development and the ability for music to be previewed and purchased.
  • The third is represented by the team of developers that brings a unique combination of deep technical expertise (in products like Skype), a team of well-accomplished executives and what the company calls Brand Ambassadors – senior reps from multiple genres who have helped artists earn over 100 Grammys.

Intercept Music is the confluence of technology and this music expertise.

The company currently markets three plans to its clients, with each offering different distribution and royalty options, as well as various marketing and reporting options. The plans are described below:

  • Intercept Distro is a basic plan for self-service music distribution with royalty collection. Artists keep 100% of the royalties while receiving unlimited releases and full analytics with reporting.
  • Intercept Artist includes all of the benefits of the basic Distro plan with added emphasis on social marketing and distribution for emerging artists. With this plan, artists receive scheduled and ad-hoc posting, social media reporting, reusable content libraries and access to other valuable features.
  • Intercept PLUS is available by invite only and is for established artists looking for a complete suite of marketing, distribution and monetization services. The PLUS plan includes everything available through the Distro and Artist plans, as well as offering a dedicated service representative, a branded online store, on-demand merchandise, additional marketing, YouTube monetization and other pro features.

Intercept PLUS is the flagship plan. Artists of this caliber often do $3-$10k/month in merchandise sales alone, at 50%+ profit. Intercept is responsible for marketing to the fan base through its social media system and shares in the profits generated. The stores are managed by intercept so both top-line revenues and bottom-line profits flow through Intercept.

Intercept Music has partnered with Ingrooves Music Group, the largest online music distribution company in the world, for worldwide distribution to streaming services and leading stores. Completing more than 50 billion transactions weekly across over 150 countries, Ingrooves supplies music to leading streaming music platforms and lists some of the world’s largest and most reputable music labels among its clients. The partnership allows Intercept Music and its clients to reach a much wider audience and start earning revenue as soon as possible by leveraging Ingrooves’ quality control systems and direct relationships with leading music streaming services.

Physical Distribution Options for Intercept Music Clients

In a press release on June 25, 2020, Intercept Music announced that it would be offering artists physical distribution through major retailers such as Amazon, FYE and Walmart (http://nnw.fm/NSrbE). The physical distribution will consist of CDs and vinyl and will serve as a supplement to the online streaming platform access provided by the company to represented artists.

“In the current climate, artists can’t play shows or otherwise engage in public at all, so they’re focusing on all other opportunities to bring in revenue,” Intercept Music President Tod Turner stated in a news release. “Our only priority is to help artists monetize music in every way, and with physical distribution added to the mix, we’re leaving no stone unturned in helping artists to earn money from their creative output.”

Creation of Preferred Stock

On June 29, 2020, Sanwire CEO Christopher Whitcomb announced that the company would be filing certificates of designation with the Nevada Secretary of State for its Series A, B and C preferred stock (http://nnw.fm/svrQt).

Speaking about this designation in a news release, Whitcomb stated, “Our paramount goal is to maintain a balanced approach between future investments and shareholder value while minimizing shareholder dilution. The effective utilization of preferred stock ensures our company can grow with the least amount of shareholder dilution.”

Sanwire is leveraging a multi-dimensional strategy that includes additional acquisitions, attracting investors and enhancing the current balance sheet while minimizing dilution for shareholders. A primary goal of these efforts is to support Intercept’s ongoing operations.

Financial Highlights

For the fiscal quarter ended June 30, 2020, Sanwire announced significant revenue growth related to the acquisitions of Intercept Music and Art is War Records. Since acquiring Intercept Music in March and Art is War Records in June, Sanwire’s revenue has increased by approximately 300% (http://nnw.fm/j0S0j). Sanwire attributes the increase in revenue to Intercept Music’s customer acquisition and the release of its PLUS plan.

For the third quarter, revenue is expected to continue an upward climb, owing largely to physical distribution plans and a rising number of PLUS subscribers. The company’s acquisition of Art is War Records is also expected to fuel this growth.

Management

Christopher M. Whitcomb is the current CEO of Sanwire Corp. and Intercept Music Inc. He is a CPA in the state of California, holding bachelor’s degrees in accounting, corporate finance and business management with a focus on real estate. A seasoned executive, his business ventures are always strongly focused on the development and financing of companies.

Whitcomb worked alongside Ralph Tashjian at SMC Entertainment Inc. and Digital Music Universe. They are currently working together again following Sanwire’s acquisition of Intercept Music, which was founded by Tashjian.

Sanwire Corp. (SNWR), closed Thursday's trading session at $0.018, up 21.6216%, on 178647 volume with 12 trades. The average volume for the last 3 months is 893,266 and the stock's 52-week low/high is $0.0035/$0.100000001.

Recent News

InsuraGuest Technologies, Inc. (TSX.V: ISGI) (OTC: ISGIF)

The QualityStocks Daily Newsletter would like to spotlight InsuraGuest Technologies, Inc. (TSX.V: ISGI) (OTC: ISGIF).

InsuraGuest Technologies (TSXV: ISGI) (OTCQB: ISGIF), a leading insurtech company disrupting the insurance industry, has changed the existing dynamic with its recently expanded Hospitality Liability coverages, in effect protecting owners of hotels and vacation rentals from paying extra for certain claims. To view the full article, visit https://ibn.fm/EUQcV

InsuraGuest Technologies, Inc. (TSX.V: ISGI) (OTC: ISGIF) is a leading global SaaS (Software-as-a-Service) company leveraging its proprietary, flagship insurtech (insurance + technology) software, InsuraGuest, which is integrated with the property management systems of hotels and vacation rentals to deliver custom Hospitality Liability coverages.

InsuraGuest’s Hospitality Liability coverages are purchased by hotels and vacation rental properties, which can address claims from guests and their room occupants. The combination of the integrated software and customized insurance provides the property liability coverages the guests benefit from in the event a loss is incurred during their stay.

The Hospitality Liability policy is offered through integration of InsuraGuest’s API with the clients’ property management systems. InsuraGuest’s platform is currently capable of integrating with approximately 71 different hotel and vacation rental property management systems, giving it access to millions of rooms worldwide.

InsuraGuest continues to pursue expansion opportunities in the United States, and has plans to expand to its distribution platform and Hospitality Liability coverages to the United Kingdom and Europe regions by third quarter 2020, as well as expansion into Asia by the end of 2020.

Protection that Enhances the Guest’s Experience

InsuraGuest’s Hospitality Liability coverages add a layer of protection for the property on a primary basis, should a guest experience an accident or theft while staying at an InsuraGuest member hotel or vacation rental property.

Market Opportunity

The U.S. hotel industry generated more than $218 billion in annual revenues in 2018, an increase of $10 billion from the previous year, according to STR’s 2019 HOST Almanac. The European market is more than double the size of the U.S. market. According to Oxford Economics, there were 6.4 billion nights stayed in the world, with 2.6 billion hotel nights stayed in Asia, 2.8 billion nights stayed in Europe, and 1.1 billion stayed nights in the United States. Additionally, $100 billion was spent on vacation rentals in the United States, where there approximately 4.5 million second homes are being managed by a third-party rental company.

With distribution in Europe and the United States, InsuraGuest’s combined demographics will total 3.9 billion nights stayed, and will more than double its vacation rental opportunities.

Within this burgeoning, high-demand industry is risk of liability to guest injury. For example, gym injuries are among the top five most common hotel accidents. Without proper hedges in place, the property may be liable in a personal injury claim or lawsuit that are not the properties fault.

Though the potential for accidents, slip and falls and mishaps can be widespread, it can be covered under the InsuraGuest Hospitality Liability policy to provide guests a worry-free and enjoyable stay that potentially increases loyalty for the property.

Investment Consideration

  • Targeting hotels and vacation rentals, a multi-billion-dollar industry
  • Providing the first line of defense in case of accident, loss or death
  • Expanding distribution reach with footing in European hotel and vacation rental markets
  • Expansion into Asia by 2020

Executive Team

Douglas Anderson, Chairman & Chief Executive Officer
Douglas Anderson has been a businessman in the real estate industry for nearly 30 years. His business expertise includes master planning and development implementation for larger-scale resorts, business parks and commercial developments across the USA and two provinces in Canada. His business endeavors include the founding of the 7th larger private equity fund in America focusing on multifamily and senior care (ROC Fund/Bridge IPG Fund). He serves as chairman/founder of a golf and winter sports ski holding company with operations in four major east coast markets and British Columbia, Canada.

Anderson earned a Bachelor of Science in consumer studies with an emphasis in architecture as an undergraduate at the University of Utah. He subsequently earned his MBA. He also attended a three-year OPM Program a postgraduate business education at Harvard Business School in Boston. Anderson is an avid skier and outdoor enthusiast.

Logan Anderson, CFO & Director
Logan Anderson (bachelor’s degree in communications, accounting and economics) holds the designation of ACA with the Chartered Accountants of Australia and New Zealand. He began his career as an associate chartered accountant in New Zealand and then Canada. This was followed by his position as controller of a management services company which was responsible for the management of numerous private and publicly traded companies. Since 1993, Anderson has served as president of Amteck Financial Corp. (and its predecessors), a private financial consulting services company servicing both private and public companies. He is a former director of 3D Systems, Inc. (NYSE: DDD), and was formerly a founder, officer, and director of Worldbid.com. Anderson has also been involved in raising funds for numerous private and public companies in all stages of their development and has been an officer and director for numerous public and private companies over the past 40 years.

Charles James Cayias, President & Director
Charles James Cayias is also the president and owner of Charles James Cayias Insurance Inc. He is a third-generation insurance professional whose creativity and artistic vision have enabled him to establish a full-service agency combined with the personal service each client deserves. His outstanding people skills, honesty, integrity and fairness are evident by his loyal and growing clientele, the majority of which are referrals who become long-time customers and friends. Cayias began his insurance career in the early 1970s and has been licensed since 1977. He is licensed in all 50 states and specializes in niche programs. He has extensive expertise in all aspects of the insurance industry including commercial insurance, employee benefits, workers’ compensation, professional liability, risk management and bonding.

Tony Sansone, COO & VP of Finance
Tony Sansone has over 30 years of financial, operations and business development experience which includes serving as CFO in the health care, foodservice distribution, manufacturing and technology sectors, including public company experience. He has held senior finance positions in the banking, telecommunications, medical products, and food & drug retailer industries, closing over $430 million of private debt, equity and line of credit financings and over $350 million of a merger, acquisitions, real estate and state incentive transactions, including due diligence, negotiations, closing, and integration. Sansone coordinated and was the executive sponsor for four ERP implementations and multiple other best-in-class software & technology solutions. He received his MBA from the University of Utah and a Bachelor of Science in accounting from Utah State University. Sansone also currently serves as president-elect of the Utah Chapter of Financial Executives International and a past president and current member of the board of trustees for Catholic Community Services of Utah. He is the proud father of three children.

Christopher J. Panos, Vice President & Director
Christopher J. Panos is a highly competitive sales professional with over 15 years of territory manager sales experience and an award-winning record of achievements. He is exceptionally well organized with a proven work history that demonstrates self-discipline, superb communication skills, and the initiative to achieve both personal and corporate goals. Panos is successful in building relationships with a large network of industry professionals in order to grow and maintain new and existing business, exceed new sales objectives and provide in-depth product training to authorized dealers and sales personnel.

Alexander Walker III ESQ, Corporate Counsel & Director
Alexander Walker III ESQ has served as director of the company since September of 2018 and as counsel to the company since July of 2018. Walker is an attorney and has been a member of the Utah Bar Association since 1987 and a member of the Nevada State Bar since 2003. His practice has involved general business litigation, in both federal and state courts, and transactional work, including securities offerings and registration, corporate formation and periodic reporting compliance. Walker has provided legal services to emerging businesses throughout his carrier and at times has served as an officer and board member as well as legal counsel public companies. His duties as legal counsel for a public company engaged in the business of ownership and operation of coal-producing properties in the western United States included oversight of corporate-related legal matters including securities reporting, corporate compliance, federal and state mining regulation, and employment law oversight. He also has served as the chair of the Mining Committee of the Energy, Natural Resources and Environmental Law Section of the Utah State Bar, a member of the board of directors of the South East Utah Energy Producers Association, the co-chair of the board of the Western Energy Training Center, a board member of the Utah Supreme Court Committee to Review the ABA Recommendations Regarding the Office of Professional Conduct, and a board member of the University of Utah Crimson Club.

Jennifer Epperson, Vice President of Sales
Jennifer Epperson has over 20 years of B2B sales experience with exceptional success history. She has grown and developed sales territories across multiple industries. Her ability to find and develop strategic relationships has given her top-level performance throughout her career. Epperson’s passion and knowledge provide an inherent ability to connect and retain relationships for the growth of the company. Throughout her professional career, she has achieved peak performance sales results and awards year after year. She captures the vision of the company and drives it forward with enthusiasm and expertise. Her commitment to providing an exceptional customer experience has been the key to her success.

Richard Matthews, Interim Financial Controller
Richard Matthews joined the InsuraGuest team in March 2019 as the interim financial controller. Leading the Finance and Audit team, Matthews is responsible for the delivery of financial services such as accounting, treasury, reporting, budgeting and insurance management, in accordance with legislative requirements and organizational policies and strategies. He has over 30 years of experience in providing professional services across a broad range of finance areas including compliance, business process, audit, and financial reporting. He holds a degree in accounting from the University of Utah and is a licensed CPA in the state of Utah.

Roger Bloss, Corporate Consultant & Board Advisor
Roger Bloss joined InsuraGuest in August of 2019 to advise the company and its board on hotel transactions, contributing his knowledge from more than 40 years in the hospitality industry. Bloss previously served in executive positions with several major hotel franchise companies and in 1996 founded Vantage Hospitality Group hotel brands. Under his leadership, Vantage became a Top 10 global hotel company and made the Inc. 500/5000 list of Americas’ fastest-growing private companies for eight straight years. Bloss was named Lodging Magazine’s “Innovator of the Year” in 2006 and 2010, and in 2009 earned a spot on HSMAI’s “Top 25 Extraordinary Minds in Sales and Marketing.” Bloss joined Red Lion Hotels Corporation (RLHC) in September 2016 in conjunction with the acquisition of Vantage.

Jim Kilduff, Board Advisor
James “Jim” C. Kilduff has nearly 40 years of experience in the insurance and risk management sectors. He is a dynamic and energetic team leader and builder with extensive experience in the changes affecting the insurance business through Gas, alternative distribution, insurtechs and program business. His skillset includes experience as chief insurance officer with Outdoorsy Insurance Group, CEO with Harbor Hill Solutions Inc., and senior vice president and chief marketing officer with State National Insurance Companies. His career has spanned MGA creation and management, insurance company management, business development and underwriting, primary insurance and reinsurance.

Don Archibald, Board Advisor
Don Archibald brings to InsuraGuest’s advisory board 54 years of experience as an insurance agent. Archibald is the founder and former owner of Archibald Clarke and Defieux (ACD Insurance), as well as the co-founder and former equity partner of Sussex Insurance, and an agent with Sussex since 2014.

InsuraGuest Technologies, Inc. (ISGIF), closed Thursday's trading session at $0.1806, even for the day, on 4,000 volume. The average volume for the last 3 months is 2,938 and the stock's 52-week low/high is $0.079300001/$0.248799994.

Recent News

Knightscope, Inc.

The QualityStocks Daily Newsletter would like to spotlight Knightscope, Inc..

Security robot manufacturer Knightscope rolled out its first autonomous product in 2015 and has watched its fanbase steadily grow during the years since then, topping 20,000 investors in February following a quick burst of new energy on the public involvement front. During a virtual fireside interview with IPO Edge in December (when Knightscope was still reporting investors at the 17,000 level), CEO William Santana Li explained the importance of the company’s Reg A+ offering that allows Knightscope to attract private investments between $500 and $10 million online without launching a public IPO, although the company maintains a plan to go public eventually (https://ibn.fm/GsMB1). You can read about what the Company can legally say at this time about a public listing here.

Knightscope, Inc., founded in 2013 and based in Mountain View, California, is a leader in the development of autonomous security capabilities and are on target to disrupt the $500 billion security industry. Knightscope’s technology uniquely combines self-driving technology, robotics and artificial intelligence.

Knightscope designs and builds Autonomous Security Robots (ASRs) that provide 24/7/365 security to the places you live, work, visit and study. The company’s client list covers public institutions and commercial business operations, including ten Fortune 1000 companies to date. These ASRs have been proven to enhance safety at hospitals, logistics facilities, manufacturing plants, schools and corporations. ASRs act as highly cost-effective complementary systems to traditional security and law enforcement officials, providing an additional advantage by continuing to offer uninterrupted patrolling capabilities across the country, despite the pandemic (note: robots are immune).

The company’s ASRs have assisted in the arrest of suspects involved in crimes ranging from armed robbery to hit-and-runs. Their machine-embedded thermal scanning capability even aided in preventing the breakout of a major fire.

The company has achieved several milestones since its creation in 2013, including:

  • Establishing itself in a 15,000-square-foot facility located in Mountain View, California, in the heart of Silicon Valley, where Knightscope designs, engineers and builds its technology;
  • Operating for more than one million hours in the field and securing contracts across five time zones;
  • Navigating through the global pandemic without interruption by continuing to operate on a daily basis across the nation and supporting clients classified as essential services; and
  • Continuing its hiring processes despite the current societal and economic disruption.

Growth Capital

With more than 10,000 investors and over $40 million raised since inception, Knightscope is poised to be an industry leader in the future of public safety and security.

The company is presently in the process of raising up to $50 million in growth capital as it prepares for a potential public listing. Knightscope has reserved ticker symbol ‘KSCP’ with Nasdaq.

Investors can buy shares exclusively through the company’s managing broker-dealer, StartEngine (http://nnw.fm/l9GLX) until July 20, 2020. Concurrent with this live offering and contingent upon various factors, including raising a sufficient amount of funds and meeting applicable listing standards, the company intends to begin preparation of an S-1 format Form 1-A and Nasdaq Capital Market application in anticipation of a possible public listing of the stock at the conclusion of the Regulation A+ offering.

Company Mission — The Greater Good

Knightscope’s long-term vision has an eye on the greater good. The company’s mission is to make the United States of America the safest nation in the world while supporting millions of law enforcement and security professionals across the country.

Crime has a negative economic impact in excess of $1 trillion annually. As crime is reduced, positive impacts will likely be realized across several aspects of society, including housing, financial markets, insurance, municipal budgets, local business and safety in general.

Knightscope CEO William Santana Li was recently interviewed by Kevin O’Leary, more commonly known as Shark Tank’s Mr. Wonderful. When asked to explain how the benefits provided by the ASRs outrank a human doing the same job, Li said, “First, just the simple presence of a physical deterrent causes criminal behavior to change. Second, the machines are self-driving cars that patrol all around and recharge themselves. They also generate 90 terabytes of data per year. No human would ever be able to process that. The robots are intended to be eyes and ears for the humans, not a one to one replacement.”

The Knightscope solution to reduce crime combines the physical presence of ASRs, sometimes referred to as proprietary Autonomous Data Machines, with real-time onsite data collection and analysis. The ASRs are fitted with eye-level 360° cameras, thermal scanning, public address announcements and various other features that work in tandem with humans to provide law enforcement officers and security guards unprecedented situational awareness.

Those 90 terabytes of data are then formatted in a useable way, so law enforcement can leverage that information and execute their responsibilities more effectively.

Public Safety Innovation

The company’s recurring revenue business model is set up to mimic the recurring societal problem of crime, and it takes into consideration the fact that innovation in the security and public safety industry has been stagnant for decades. Because the traditional practices of the sector have remained unchanged for years, automation has potential to drive substantial cost savings — and significant improvement in capabilities.

Human security guards are one of both the largest expenses and the largest liabilities for companies. Knightscope’s robots are offered at an effective price of $4 to $11 per hour, compared with approximately $85 and $30 per hour for an armed off duty law enforcement officer and an unarmed security guard, respectively.

This innovation has the potential to drive considerable cost savings. Based on these estimates, manufacturing costs can be recovered as soon as the first year of operation.

Product Offerings

The company has four patents and a framework of unique intellectual property. Knightscope currently offers a K1 stationary machine, a K3 indoor machine and a K5 outdoor machine. A K7 multi-terrain four-wheel version is in development.

The ASRs autonomously patrol client sites without the need for remote control, providing a visible, force multiplying, physical security presence to help protect assets, monitor changes in the area and deter crime. The data is accessible through the Knightscope Security Operations Center (KSOC), an intuitive, browser-based interface that enables security professionals to review events generated by the ASRs providing effectively ‘mobile smart eyes and ears’.

The ASRs and all the related technologies were developed ground up by the Company and are Made in the USA.

Management Team

Chief Executive Officer William Santana Li is a veteran entrepreneur, a former executive at Ford Motor Company and the founder of GreenLeaf, a company that grew to be the world’s second-largest automotive recycler and is now part of LKQ Corporation (NASDAQ: LKQ).

Chief Client Officer Stacy Dean Stephens brings his experience as a former Dallas law enforcement officer, as well as his skills as a seasoned entrepreneur, to assist on the client acquisition side.

Chief Intelligence Officer Mercedes Soria is an award-winning technologist and former Deloitte software engineer.

Chief Design Officer Aaron Lehnhardt brings over two decades of two- and three-dimensional product and industrial design in modeling and VR to the table, on top of his experience as a senior designer at Ford Motor Company.


Recent News

chart

TAAT Lifestyle & Wellness Ltd. (CSE: TAAT) (OTCQB: TOBAF)

The QualityStocks Daily Newsletter would like to spotlight TAAT Lifestyle & Wellness Ltd. (CSE: TAAT) (OTCQB: TOBAF).

TAAT(TM) (CSE: TAAT) (OTCQB: TOBAF) (FRANKFURT: 2TP2) today announced the availability of a broadcast titled, “Beyond Tobacco: TAAT Innovation Delivers New Smoking Alternative.” The piece covers health and wellness as a top priority in today’s world, which has created a global climate of consumers clamoring for choices that offer the same experiences they’ve come to enjoy but with different ingredients. TAAT meets this growing demand in bringing the “same format, different ingredients” model to the smoking market like no one before. With senior leadership combining extensive experience in “big tobacco,” the life sciences company has developed its products to closely replicate a conventional cigarette while changing the composition to offer a tobacco-free alternative. To view the full press release, visit https://ibn.fm/ATEQF

TAAT Lifestyle & Wellness Ltd. (CSE: TAAT) (OTCQB: TOBAF) is a life sciences company dedicated to giving legal-aged smokers the choice to keep the smoking experience that they enjoy with no nicotine and no tobacco.

The key players of TAAT Lifestyle & Wellness are from leading tobacco brands. They are guiding the mission with the company’s proprietary product, TAAT(TM), which uses the company’s proprietary Beyond Tobacco(TM) base material. The base material undergoes a 14-step process to taste and smell just like tobacco and uses a patent-pending refinement technique.

This provides the company with unique opportunities on the global tobacco market, which was estimated at $849 billion in 2019, with approximately 1.3 billion people using tobacco in some form worldwide (https://nnw.fm/bvKFL).

TAAT Lifestyle & Wellness was founded in 2006 and is headquartered in Vancouver, Canada, with operations in Las Vegas, Nevada.

TAAT(TM)

TAAT is a smokable alternative to tobacco cigarettes using the Beyond Tobacco base material, which contains zero tobacco and zero nicotine. The current TAAT offering comes in three varieties: Original, Smooth and Menthol, which were launched during Q4 2020 in Ohio. The company’s Ohio tobacco wholesaler also distributes for major tobacco industry names such as Altria, RJ Reynolds (a subsidiary of British American Tobacco) and ITG.

The TAAT Beyond Tobacco experience was created to replicate the sensory elements of smoking a tobacco cigarette. Market testing in California and Nevada reached a consensus that TAAT products offered no significant differences in experience when compared to tobacco cigarettes, in terms of the following aspects:

  • Visual – the nearly identical product packaging and enhanced smoke volume
  • Auditory – the “crackling” sound of the base material when it is ignited
  • Smell – when burning, TAAT emits a tobacco-like scent
  • Taste – the patent-pending Beyond Tobacco base material undergoes a refinement process that creates a tobacco-like taste
  • Touch – TAAT satisfies the “hand-to-mouth” fixation and motor habits, such as flicking ashes

TAAT Beyond Tobacco Targeting Current Smokers

TAAT Lifestyle & Wellness is currently targeting the market of legal-aged smokers with its proprietary product. The company aims “not to create a new problem, but to solve an existing one.” TAAT Lifestyle & Wellness offers a non-addictive alternative to tobacco, with several competitive advantages making it a promising option on the United States market, such as:

  • Price – TAAT can be offered at a lower price than competing products in the tobacco category, which adds to the propositioned value for current legal-aged smokers.
  • Experience – TAAT appeals to current smokers who wish to give up the tobacco and nicotine but keep the smoking experience they enjoy.
  • Branding/Packaging – TAAT is American-grown and American-made, with its Beyond Tobacco base material serving as a legacy to the combustible tobacco products.

The current alternatives to cigarette smoking do not offer a comparable experience. Previously marketed products, like vaping, proved difficult for some legal-aged smokers to adopt, as the experience was too different from traditional cigarettes.

Market Outlook

In 2016, the United States tobacco market was valued at over $100 billion, a number that’s expected to grow over the next decade (https://nnw.fm/yd8oP). In terms of volume, over 215 billion cigarettes were sold to roughly 34 million adults in the United States in 2018. These numbers represent almost 14% of the adult population. Of those, almost two-thirds smoked more than 15 cigarettes in one day. A standard pack is comprised of 20 cigarettes.

The company’s Beyond Tobacco, as a non-tobacco product, has a price-driven consumer advantage in many states. While state taxes on traditional cigarettes vary, most tend to average around $1.82 per pack. Washington D.C. is on the higher end of the tax spectrum at $4.50 per pack, whereas Missouri is only $0.17 per pack (https://nnw.fm/D3WnT).

TAAT Lifestyle & Wellness estimates that, if one pack of TAAT Beyond Tobacco was sold at 20% of all United States tobacco points of sale, the product would capture 0.25% of the market, the equivalent of approximately 2.7 million cartons of cigarettes per year.

Management Team

Setti Coscarella is the Chief Executive Officer of TAAT Lifestyle & Wellness Ltd. He is experienced in investment banking, private equity and entrepreneurship. In 2017, Mr. Coscarella was the lead strategist for Reduced-Risk Products at Philip Morris International. While there, he worked with thousands of smokers to better understand how to position smoking alternatives, developing programs that could help smokers convert to reduced-risk products. Mr. Coscarella holds an MBA from the Schulich School of Business, specializing in finance, marketing and corporate strategy. He also has a Bachelor of Science in mathematics and physics from the University of Toronto.

Tim Corkum is the company’s Chief Revenue Officer. He has a lengthy history in the tobacco industry, having served 21 years at Philip Morris International. Mr. Corkum has experience leading the international commercialization of combustible cigarettes and working on reduced-risk product offerings. During his 21-year tenure, he held senior positions in business development, sales strategy, key account management and corporate affairs. He holds a BA from Carleton University with a concentration in law.

Joe Deighan is Founder of TAAT Lifestyle & Wellness and oversees research and development. He is the founder of vape liquid ‘JJuice’, created in 2012. JJuice was distributed across all of the United States and in 26 other countries, alongside the private label production that was done for other brands. Mr. Deighan sold JJuice in a cash deal that was valued at over $800,000 in 2017. He currently handles all R&D and production for Beyond Tobacco, knowing the product better than anyone else in the company.

TAAT Lifestyle & Wellness Ltd. (TOBAF), closed Thursday's trading session at $3.8659, off by 6.2858%, on 309915 volume with 750 trades. The average volume for the last 3 months is 232,213 and the stock's 52-week low/high is $0.100000001/$4.73999977.

Recent News

Excellon Resources Inc. (TSX: EXN) (NYSE American: EXN) (FSE: E4X2)

The QualityStocks Daily Newsletter would like to spotlight Excellon Resources Inc. (TSX: EXN) (NYSE American: EXN) (FSE: E4X2).

Excellon Resources (TSX: EXN) (NYSE American: EXN) (FSE: E4X2), a silver and base metals producer with operations in Mexico and precious metal exploration projects in Mexico, Idaho and Germany, has announced a new discovery. The discovery of high-grade silver mineralization comes at Grauer Wolf, the fourth target drilled at EXN’s Silver City project (https://ibn.fm/1vKtG). Also today, the company was featured in a publication from MiningNewsWire, examining how an official from the Indonesian government has confirmed recent reports that the country’s government will start early talks with electric vehicle manufacturer Tesla Inc. (NASDAQ: TSLA) over a possible investment in Li-ion battery development in the country. Indonesia’s deputy head for mining and investment coordination, Septian Hario Seto, was the first to reveal news of the investment proposal. This development would boost Indonesia, which is already the largest producer of nickel globally. Nickel is an essential ingredient in Li-ion battery production, with the batteries being used in electric vehicles.

Excellon Resources Inc. (TSX: EXN) (NYSE American: EXN) (FSE: E4X2) (“Excellon” or the “Company”) is a silver and base metals producer with precious metal exploration and development projects in Mexico, Idaho and Germany. Since being founded in 1987, the Company has been advancing a precious metals growth pipeline focused on creating wealth for its stakeholders by realizing strategic opportunities in the silver and gold markets.

Excellon is an active and influential member of the Mining Association of Canada (“MAC”). The Company implements a practical, best-in-class management system that addresses the safety, health, security, environmental and community aspects of its operations, per the UN Sustainable Development Goals. On each project, the Company incorporates MAC’s Towards Sustainable Mining Initiatives and other world-class best practices with the objective of constantly improving its safety systems, training and hazard recognition.

Precious Metals Growth Pipeline

The Company is advancing a precious metals growth pipeline that includes: Platosa, Mexico’s highest-grade silver mine since production commenced in 2005; Kilgore, a high-quality gold development project in Idaho with strong economics and significant growth and discovery potential; and an option on Silver City, a high-grade epithermal silver district in Saxony, Germany, with 750 years of mining history and no modern exploration.

Maintaining and developing this pipeline presents the Company with enhanced opportunities in the expanding precious metals market, which was valued at $193.3 billion worldwide in 2020 (https://nnw.fm/6nv5f). This market is expected to increase at a compound annual growth rate (“CAGR”) of 9% from 2020 to 2027, resulting in an estimated $362.1 billion market size in 2027 (https://nnw.fm/6nv5f). Global market demand was calculated at 22,581.8 tons in 2020 and is expected to grow to 36,501.1 tons in 2027, achieving a CAGR of 3.5% (https://nnw.fm/6nv5f).

Excellon reported strong results in terms of both production and average pricing at the end of Q4 2020, including:

  • Silver – 355,581 oz – $24.46
  • Lead – 2,223,465 lbs. – $0.87
  • Zinc – 2,452,728 lbs. – $1.21

Compared to Q4 2019, Excellon’s silver production increased by 37%, lead increased by 32% and zinc increased by 19% in Q4 2020 (https://nnw.fm/4C0P7).

Platosa Mine – Silver, Lead, Zinc – Production, Development & Exploration

The Platosa Mine is located 5 km north of Bermejillo, Durango, Mexico, on a 14,000-hectare property. The mine commenced production in 2005 as an underground operation and is 100% owned and operated by Excellon. The Company is mining massive sulfide ores rich in silver, lead and zinc from a series flat-lying massive sulfide bodies (mantos) in a carbonate replacement deposit system. Historically, the mining method was a modified room and pillar method, which transitioned to cut-and-fill in recent years and overhand-cut-and-bench in 2020. The ore produced from the mine is transported 200 km south for processing at the Company’s 100% owned Miguel Auza mill.

Kilgore Project – Gold – Exploration & Resource Growth

The Kilgore Project is located in Clark County, situated in eastern Idaho in the United States. The project area is 100% owned and operated by Excellon. While still in the exploration and development phase, the primary target on the 13,627-acre site is an epithermal gold system. The property itself has historical mining that dates back to the 1930s, with modern mineral exploration beginning in the 1980s. The Kilgore Project displays characteristics similar to Kinross Gold’s Round Mountain Mine, which has produced more than 15 million ounces of gold since operations began in 1977.

Evolución Project – Mineral Processing, Resource Growth & Exploration

The Evolución Project is located in Miguel Auza, Zacatecas, Mexico, and hosts a large gold, silver, lead and zinc epithermal within a 45,000-hectare property that is 100% owned by Excellon. The site includes a processing facility with a mill and flotation circuit which processes ore from Excellon’s Platosa mine. The facility has a capacity of 800 tons per day, with a 650 ton-per-day ball mill in operation and a second 150 ton-per-day ball mill on standby. Excellon is looking at opportunities for toll milling, expansion and economic study of the mineral resource and grassroots exploration. Importantly, the project covers an unexplored 35-kilometer strike of the Fresnillo silver trend, the richest silver belt in the world.

Silver City Project – Exploration

Excellon holds an option to acquire the 16,400-hectare Silver City Project in Saxony, Germany. Initial drilling results in 2020 confirmed the presence of a high-grade, district-scale epithermal silver system over more than 12 kilometers of strike. The Company is now focused on defining wider zones of mineralization (https://nnw.fm/jMah9). Silver City was mined from the 11th to late-19th century, until Germany moved off the silver standard in 1873. The deposits in the area were exceptionally high grade, with historical records indicating grades well in excess of 1,000 g/t silver.

Oakley Project – Exploration

The Oakley Project, located in Oakley, Idaho, is an exploration project with land holdings of approximately 7,000 acres. The project hosts gold-silver, epithermal hot spring-type mineralization at two targets: Blue Hill Creek and Cold Creek, and detachment-related gold-silver mineralization at Matrix Creek. The Company has granted Centerra (U.S.) Inc. an option to earn in to a 70% interest by, among other things, spending up to US$7 million in exploration expenditures on the project prior to May 2026.

Management Team

Brendan Cahill is the President & Chief Executive Officer of Excellon Resources Inc. He was previously Vice President Corporate Development of Pelangio Exploration Inc., a junior gold exploration company active in Ghana, West Africa. Mr. Cahill is a board member of the Mining Association of Canada, Group Eleven Resources Ltd., and Kore Mining Inc. He holds a law degree from the University of Western Ontario and an undergraduate degree from the University of Toronto.

Alfred Colas is the Company’s Chief Financial Officer. Most recently, he held the title of CFO of Arch Corp., a Toronto-based private-equity investment firm. Mr. Colas has over 18 years of experience in the mining industry. He is a sitting board member for a housing corporation affiliated with the University of Toronto and is a Chartered Professional Accountant. Mr. Colas completed a Bachelor of Commerce at the University of Toronto.

Paul Keller is Excellon’s Chief Operating Officer. He has over 30 years of industry experience in mining and mine development operations. He previously served as the Senior VP of Major Projects and COO of Trevali Mining. He has experience in building mines from greenfield through permitting, design and operation. Mr. Keller holds a Bachelor of Engineering – Mining from Laurentian University.

Ben Pullinger is the Senior Vice President Geology & Corporate Development for Excellon. Ben brings over 15 years of experience in advancing projects from early stage exploration through to production. Most recently, he was Vice President Exploration at Roxgold Inc., where he made a significant contribution toward growing the 55 Zone at Yaramoko Project into a producing mine. Mr. Pullinger serves on the board of Orford Mining. He is a Professional Geologist (Ontario) and holds an Honors Degree in Geology from the University of Johannesburg.

Excellon Resources Inc. (EXN), closed Thursday's trading session at $3.40, off by 5.0279%, on 96890 volume with 481 trades. The average volume for the last 3 months is 75,526 and the stock's 52-week low/high is $2.19499993/$3.90000009.

Recent News

CNS Pharmaceuticals Inc. (NASDAQ: CNSP)

The QualityStocks Daily Newsletter would like to spotlight CNS Pharmaceuticals Inc. (NASDAQ: CNSP).

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today confirmed that the clinical program for Berubicin is on track to start enrolling patients in March 2021. CNS' lead product candidate, Berubicin, is a novel anthracycline and the first anthracycline to cross the blood-brain barrier and is in development for the treatment of a number of serious brain and CNS oncology indications. To view the full press release, visit http://ibn.fm/DEZCQ

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is a clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system.

The company was founded in 2017 and is headquartered in Houston, Texas.

Organ Targeted Therapeutics

The company’s lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin also has potential to treat other central nervous system malignancies. Based on limited clinical data, Berubicin appears to be the first anthracycline to cross the blood brain barrier in the adult brain, and it was the subject of a successful Phase 1 study which found the MDT and produced efficacy data as well.

CNS holds a worldwide exclusive license to the Berubicin chemical compound. The company has acquired all requisite data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase I clinical trial of Berubicin in malignant brain tumors. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. In 2017, CNS entered into a collaboration and asset purchase agreement with Reata.

CNS intends to explore the potential of Berubicin to treat other diseases, including pancreatic and ovarian cancers and lymphoma. The company is also examining plans to develop combination therapies that include Berubicin.

CNS estimates that more than $25 million in private capital and grants were invested in Berubicin prior to the company’s $9.8 million IPO in November 2019.

CNS intends to submit an IND for Berubicin during the fourth quarter of 2020 and expects to commence a Phase II clinical trial of Berubicin for the treatment of GBM in the U.S. in Q1 2021. A sub-licensee partner was awarded a $6 million EU/Polish National Center for Research and Development grant to undertake a Phase II trial of Berubicin in adults and a first-ever Phase I trial in pediatric GBM patients in Poland in 2021.

The company’s second drug candidate, WP1244, is a novel DNA binding agent licensed from the MD Anderson Cancer Center. In preclinical studies, WP1244 proved to be 500-times more potent than the chemotherapeutic agent, daunorubicin, in inhibiting tumor cell proliferation. The company has entered into a sponsored research agreement with the MD Anderson Cancer Center to further the development of WP1244.

CNS Pharmaceuticals recently engaged U.S.-based Pharmaceutics International Inc. and Italian BSP Pharmaceuticals SpA for the production of the Berubicin drug product. The company has implemented a dual-track manufacturing strategy to mitigate COVID-19-related risks, diversify its supply chain and provide for localized availability of Berubicin. CNS has already completed synthesis of Berubicin’s active pharmaceutical ingredient (API) and has shipped the API to both manufacturers in order to prepare an injectable form of Berubicin for clinical use.

Global Brain Tumor Therapeutics Market

The high recurrence rate of malignant brain tumors is due to reappearance of focal masses, indicating that a sub-population of tumor cells in these cancers may be insensitive to current therapies and may be responsible for reinitiating tumor growth. This necessitates the development of newer drugs in the market that demonstrate greater efficacy in treating such aggressive cancers.

A global increase in neurological disorders has placed increased attention on cancers of the brain over the past decade. Neurological disorders are becoming one of the most prevalent types of disorders, due to longer life expectancy, greater exposure to infection and an increasingly sedentary lifestyle. Because few treatments for primary and metastatic cancers of the brain exist, costs are high and have acted as a restraint for the brain tumor therapeutics market.

Despite progress in surgery, radiotherapy and chemotherapeutic strategies, effective treatments for brain cancer are limited by a lack of specific therapies for the brain and the difficulty in transporting therapeutic compounds across the blood brain barrier. Therefore, there is a significant need for novel and effective therapeutic drugs and strategies that prolong survival and improve quality of life for brain tumor patients.

Several companies are making significant investments into R&D, which is expected to bring more treatment options to the market in the near future. Industry reports consistently project continued growth in the market.

One report estimates that the global brain tumor therapeutics market will reach a valuation of $2.74 billion in 2023, with the market expected to register a CAGR of 11% during the forecast period from 2018 to 2023. Another report projects that the global brain tumor therapeutics market will reach $3.4 billion by 2025, up from $2.25 billion in 2019 (http://nnw.fm/eDUjp).

Management Team

John M. Climaco is the CEO of CNS Pharmaceuticals. For 15 years, Climaco has served in leadership roles for a variety of health care companies. Recently, Climaco served as the Executive Vice President of Perma-Fix Medical S.A, where he managed the development of a novel method to produce Technitium-99. Climaco also served as President and CEO of Axial Biotech Inc., a DNA diagnostics company. In the process of taking Axial from inception to product development to commercialization, Climaco forged strategic partnerships with Medtronic, Johnson & Johnson and Smith & Nephew.

Christopher Downs, CPA, is the company’s Chief Financial Officer. Downs previously served as Interim Chief Financial Officer and Executive Vice President of InfuSystem Holdings Inc. (NYSE: INFU), a supplier of infusion services to oncologists in the United States. Downs holds a Bachelor of Science from the United States Military Academy at West Point, an MBA from Columbia Business School and a Master of Science in Accounting from the University of Houston-Clear Lake.

Dr. Donald Picker is the Chief Scientific Officer of CNS. Picker has over 35 years of drug development experience. Prior to joining CNS, Picker worked at Johnson Matthey, where he was responsible for the development of Carboplatin, one of the world’s leading cancer drugs, which was acquired by Bristol-Myers Squibb with annual sales of over $500 million. In addition, he oversaw the development of Satraplatin and Picoplatin, third-generation platinum drugs currently in late-stage clinical development.

Sandra L. Silberman, M.D., Ph.D., is the Chief Medical Officer of CNS Pharmaceuticals. Silberman is a hematologist/oncologist who earned her B.A., Sc.M. and Ph.D. from the Johns Hopkins University School of Arts and Sciences, School of Public Health and School of Medicine, respectively, and her M.D. from Cornell University Medical College. She then completed both a clinical fellowship in hematology/oncology and a research fellowship in tumor immunology at the Brigham & Women’s Hospital and the Dana Farber Cancer Institute in Boston, Massachusetts. Silberman has played key roles in the development of many drugs, including Gleevec(TM), for which she led the global clinical development at Novartis. Silberman advanced several original, proprietary compounds into Phases I through III during her work with leading biopharmaceutical companies, including Bristol-Myers Squibb, AstraZeneca, Imclone and Roche.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP), closed Thursday's trading session at $2.88, off by 2.3729%, on 308168 volume with 1,659 trades. The average volume for the last 3 months is 2,696,951 and the stock's 52-week low/high is $1.25820004/$5.61999988.

Recent News

Kaival Brands Innovations Group Inc. (KAVL)

The QualityStocks Daily Newsletter would like to spotlight Kaival Brands Innovations Group Inc. (KAVL).

Kaival Brands (OTCQB: KAVL), a company focused on generating stockholder value by incubating innovative products into mature and dominant brands, is the exclusive global distributor of all products manufactured by Bidi Vapor LLC. Bidi Vapor's primary offering, the Bidi(R) Stick, is the fastest-growing closed system vaping product in the U.S. and the only vape product on the market with an ecologically friendly, mass-recycling program. Kaival Brands today announced three new distribution partners for Bidi Vapor's vaping products. To view the full press release, visit http://ibn.fm/fCG8v

Kaival Brands Innovations Group Inc. (KAVL) is focused on growing and incubating innovative and profitable products into mature, dominant brands. It aims to develop internally, acquire or exclusively distribute these products, helping them grow into market-share leaders by providing superior quality that is recognizable in their individual industries.

Formerly known as Quick Start Holdings Inc., the company changed its name to Kaival Brands Innovations Group Inc. (also known as Kaival Brands) in July 2019. Headquartered in Grant, Florida, the company commenced business operations on March 9, 2020.

Bidi™ Stick – Revolutionizing the Vaping Experience

On March 9, 2020, Kaival Brands entered into a partnership with Bidi Vapor LLC. The latter granted Kaival Brands exclusive global distribution rights for the innovative Bidi™ Stick.

Bidi™ Stick is a completely self-contained disposable product that is tamper-proof and recyclable. The innovative product is made from high-quality components and equipped with a long-lasting battery and class A nicotine. Its product engineering also includes a sensitivity control system, along with a proven mechanism designed to help identify and eliminate counterfeit products.

Available in 11 flavors, the Bidi™ Stick offers a premium vaping experience for adult consumers only. From its packaging design to its marketing strategies, Bidi Vapor makes sure that everything is compliant with government regulations.

On March 31, 2020, Kaival Brands partnered with QuikfillRx Digital as a digital service provider to help promote and commercialize the Bidi™ Stick. As a direct result of the partnership, Kaival Brands received back-to-back orders for the vaping device, totaling approximately $135,000, from sizable national convenience chains.

On September 8, 2020, the company announced that Bidi Vapor had submitted its Premarket Tobacco Product application (PMTA) to the U.S. Food and Drug Administration (FDA) for review. In total, over 285,000 pages of research, studies and surveys were submitted to support the application of Bidi™ Stick’s 11 variants.

“We are confident that, upon review, the FDA will authorize Bidi Vapor’s Bidi™ Stick for continued marketing in the United States,” Niraj Patel, President and CEO of Kaival Brands, stated in a news release (http://nnw.fm/unAyG).

Bidi Vapor is an industry leader in recycling – a position that was furthered through the creation of the Bidi Cares Initiative. The program encourages users to recycle their used Bidi™ Sticks instead of trashing them. As motivation, Bidi Vapor offers a free Bidi™ Stick for every 10 used devices recycled by a consumer. Kaival Brands is the exclusive recycling provider for the initiative.

Partnership Impact and Market Outlook

Bidi Vapor is a related party to Kaival Brands, as it is owned by Kaival Brands CEO Nirajkumar Patel. Patel is also the majority stockholder of Kaival Brands, placing both entities under common control.

The partnership has already had a positive impact on Kaival Brands, helping the company expedite growth, as evidenced by its Q2 financial results. According to Kaival Brands’ consolidated fiscal results for the quarter that ended on April 30, 2020, its revenues grew to approximately $22.5 million from no revenue in the same quarter of 2019. The company also scored a gross profit of $4.2 million for the three-month period. Net income was reported at $2.8 million for the quarter, compared to a net loss of about $4,000 in the second quarter of 2019. The company ended the second quarter of 2020 with a cash balance of $2 million (http://nnw.fm/44sq4).

The positive results are primarily an effect of Bidi™ Stick distribution amid the growing worldwide demand for high-quality vape products, as Patel explained in a news release. “Our focus now is to continue to increase revenues by increasing Bidi Vapor’s market share in the vaping industry,” he added.

Internationally, Kaival Brands has already taken steps to expand distribution of the Bidi™ Stick into Guam, Canada, the European Union, the United Kingdom, Australia and New Zealand.

To this end, the company has set up a market engagement and sales force to reach a higher volume of retail and wholesale customers. It also created a dedicated customer support team to provide high-quality service and an enhanced customer experience.

Kaival Brands is dedicated to developing innovative and viable options for adults who use tobacco and vape products and want a premium experience. The company wants to set higher standards to transform perceptions and elevate consumer experience in the vape and CBD industries, with a goal of increasing market share in the ever-growing vaping industry. In 2019, the reported global market for the vaping industry alone was $12.4 billion. These forecasts indicate a potential CAGR of 23.8% through 2027.

Cancellation of 300 Million Shares of Common Stock

In August 2020, the company canceled 300 million shares of common stock, marking a 52.1 percent reduction in its issued and outstanding shares of common stock (http://nnw.fm/W7s9T). Currently, the company’s outstanding common shares total 277,282,630. The cancelation was done in exchange for three million shares of Series A Preferred Stock. The Series A Preferred Stock cannot be converted before November 2023, barring any event that may trigger early conversion.

According to Patel, this move will benefit all shareholders and help maintain stability of the market pricing of remaining common stock. The overall goal is to increase value for long-term investors.

Management Team

Nirajkumar Patel is the CEO, CFO, President, Treasurer and Director of Kaival Brands and owner of Bidi Vapor LLC. In 2004, Patel received a Bachelor of Science in pharmaceutical sciences from AISSMS College of Pharmacy in Prune, India. He moved to the United States in 2005, and he continued his education at the Florida Institute of Technology, where he graduated in 2009 with a master’s degree in medicinal and pharmaceutical chemistry. He currently holds a Six Sigma Black Belt Certification.

Eric Mosser is the COO, Secretary and Director of Kaival Brands. Mosser attended Arizona State University, where he studied business management. In 2004, he graduated from Rio Salado College with an associate degree in applied science in computer technology.

Kaival Brands Innovations Group Inc. (KAVL), closed Thursday's trading session at $2.60, off by 3.7037%, on 234752 volume with 353 trades. The average volume for the last 3 months is 617,765 and the stock's 52-week low/high is $0.016/$3.65000009.

Recent News

Uranium Energy Corp. (NYSE American: UEC)

The QualityStocks Daily Newsletter would like to spotlight Uranium Energy Corp. (NYSE American: UEC).

Uranium Energy (NYSE American: UEC) president and CEO Amir Adnani was featured on a recent episode of The Bell2Bell Podcast (https://ibn.fm/6mYtD), a podcast series focused on providing informative updates and exclusive interviews with executives leading companies that are operating in fast-moving industries. Under Adnani’s guidance, Uranium Energy advanced from concept to U.S. production in its first five years of operation; UEC currently has an extensive pipeline of low-cost, near-term production projects.

Uranium Energy Corp. (NYSE American: UEC) is a U.S.-based uranium mining and exploration company that controls one of the country’s largest historical uranium exploration and development databases. Founded in 2003, UEC is headquartered in Corpus Christi, Texas. Properties acquired by the company are primarily located within the United States, including Texas, New Mexico, Colorado, Arizona and Wyoming.

Through the use of historical exploration data, UEC has been able to target and acquire properties that have already been subject to exploration and development by senior energy firms in the past.

UEC is well-financed to aggressively pursue key developmental targets. The company is also well-positioned to capitalize on rising global demand for more uranium and more carbon-free energy, and it uses technology that contributes to a cleaner environment.

In-Situ Recovery (ISR) Technology

In-situ recovery (ISR) technology is a low-cost and environmentally friendly mining technology utilized by UEC at its fully licensed projects, including Palangana, Burke Hollow, Goliad and Reno Creek.

ISR technology involves the circulation of naturally occurring and benign groundwater through a uranium ore body. This natural water (that is unfit for any other use) plus oxygen is pumped into injection wells through the uranium ore body, where the uranium in the host sandstone is oxidized and solubilized. The uranium bearing groundwater continues to flow through the sandstone to the extraction wells, where it is pumped to the surface. This water proceeds to an ion exchange unit (like a big water-softener) for uranium removal, then is pumped back to the wellfield and again re-circulated through the ore body. This recirculation of the same groundwater continues over and over, until the uranium in the sandstone is depleted.

In the ion exchange process, the extracted uranium in solution is concentrated on resin beads for transport to the Hobson Processing Facility. There, the uranium then undergoes several simple processing steps before being dried and packaged as “yellowcake” that will be transported to a conversion facility, where its sold to UEC customers.

Hobson Processing Plant

Hobson is the centerpiece in UEC’s hub and spoke production strategy, with low-cost satellite ISR operations all within relatively short trucking distance. The plant is fully licensed and currently on standby with an annual production capacity of 2 million pounds of U3O8. The spokes of the UEC strategy include the Palangana, Burke Hollow, Goliad, Salvo and Longhorn ISR projects. With an improvement in uranium prices that justify production, UEC plans to restart the plant with uranium loaded resins originating first from Palangana and then followed by Burke Hollow. UEC has applied for a license amendment with the Texas Commission on Environmental Quality to increase the Hobson facility’s production capacity to 4 million pounds per year.

Current Projects

Uranium Energy’s current project portfolio includes:

  • Texas – Hobson Processing Plant, Palangana Mine, Goliad, Burke Hollow, Salvo and Longhorn
  • Wyoming – Reno Creek
  • Paraguay – Oviedo, Yuty and Alto Paraná
  • New Mexico – Dalton Pass and C de Baca
  • Colorado – Long Park and Slick Rock
  • Arizona – Anderson, Los Cuatros and Workman Creek
  • Canada – Diabase

Uranium Market Outlook

The long-term fundamentals underlying the market continue to strengthen. Currently, UEC sees an annual gap of about 40 million pounds between uranium production and utility requirements. Current forecasts show this structural deficit persisting at least through 2026 and then expanding further to almost 70 million pounds per year by 2030. While secondary supplies have been filling the void, those supplies are not a sustainable long term supply source. There are different estimates on timing, but it is clear secondary supply (that includes inventory drawdowns) will be insufficient to fill the projected gap between supply and demand, and new production will be required. As this transition evolves, the market will become more production cost driven as opposed to inventory driven.

Higher priced contracts that have supported high production costs are continuing to roll out of producer and utility supply portfolios. These higher priced contracts are not replaceable, with current market prices below production costs for the vast majority of western producers. This will likely continue the trend of production cuts and deferrals until prices rise sufficiently to sustain long-term mining operations.

In the U.S., some of the foreign State-Owned Enterprise (“SOE”) supply that has been flooding the market will be reduced. Last year, the U.S. Department of Commerce negotiated an amendment to the Agreement Suspending the Antidumping Investigation on Uranium from the Russian Federation that reduces America’s dependence on Russian natural uranium concentrates by up to 75% from prior levels. Due to a prolonged weak pricing environment from an influx of price insensitive supply from SOEs, U.S. production is effectively zero, less than 1% of U.S. requirements.

On the demand side of the equation, further upside market pressure also appears likely to evolve as utilities return to a longer-term contracting cycle to replace expiring contracts. Over the longer term, there continues to be underlying and increasing demand building, as the globe continues a push toward carbon-free energy goals. Those goals will require the 24/7, base load, clean energy that nuclear power provides as part of the overall supply mix. A good example of that policy messaging came from Japan’s energy minister, who recently said he considers nuclear energy “indispensable” if the country is to meet its net-zero carbon emission goals.

Exacerbating the overall supply picture, lead times for new production typically range from seven to 10 years or longer. The market appears to be within the time frames required for investment to bring new supply online to meet those lead times. However, prices are not yet at levels that incentivize future production, increasing the probability of the potential for less supply than the market is currently pricing in. All things considered, UEC believes the supply and demand fundamentals should continue to exert upward pressure on uranium prices.

Management Team

Spencer Abraham is Chairman of the Board for UEC. He served as the 10th U.S. Secretary of Energy from 2001 to 2005. He is an honors graduate of Michigan State University and Harvard Law School, and he was a law professor at the Thomas M. Cooley School of Law. He was elected chairman of the Michigan Republican Party in 1983 and later served as deputy chief of staff in the office of the vice president and as co-chairman of the National Republican Congressional Committee. In 1994, Mr. Abraham was elected to the United States Senate from Michigan and has also served as a director of Occidental Petroleum and as the non-executive chairman of AREVA’s U.S. board.

Amir Adnani is the Chief Executive Officer, President and Director of Uranium Energy. He advanced the company from concept to United States production within its first five years. Mr. Adnani has developed an extensive pipeline of low-cost and near-term production projects. He is the founder and Chairman of GoldMining Inc. (TSX: GOLD) (OTCQX: GLDLF), a gold-resources acquisition and development firm. He is also the Chairman of Uranium Royalty Corp. (TSX.V: URC). Mr. Adnani holds a Bachelor of Science from the University of British Columbia. He is a director of the University’s Alumni Association.

Scott Melbye is the company’s Executive Vice President. He is a 36-year veteran of the nuclear energy industry and has held numerous leadership positions in major uranium mining firms. He is also the current President, CEO and Director of Uranium Royalty Corp. He is an advisor to the Nuclear Energy Program at the Colorado School of Mines. Prior to his work at Uranium Participation Corp., Mr. Melbye worked for Cameco Inc. for 22 years. He received a Bachelor of Science in Business Administration with a specialization in International Business from Arizona State University in 1984.

Bruce Nicholson is the company’s Vice President of Corporate Development. He has spent 16 years as a specialist in the industry, serving major United States and European banks, broker-dealers and investment funds. Mr. Nicholson is a member of the Minerals Economics and Management Society, Minerals Industry Analyst Group, and the New York Society of Securities Analysts. He graduated with an MBA in Finance from Rutgers University in 1995 and is a CFA charter holder.

Uranium Energy Corp. (UEC), closed Thursday's trading session at $2.22, off by 3.8961%, on 5014069 volume with 14,000 trades. The average volume for the last 3 months is 4,467,813 and the stock's 52-week low/high is $0.349999994/$2.55999994.

Recent News

Clean Power Capital Corp. (CSE: MOVE) (FWB: 2K6) (OTC: MOTNF)

The QualityStocks Daily Newsletter would like to spotlight Clean Power Capital Corp. (CSE: MOVE) (FWB: 2K6) (OTC: MOTNF).

Clean Power Capital (CSE: MOVE) (FWB: 2K6) (OTC: MOTNF), an investment company, has announced that the third-generation technology of PowerTap Hydrogen Fueling Corp., an investee company of Clean Power, has electricity-generating capability. Clean Power made the announcement as Texas has experienced severe weather resulting in widespread electricity outages. In the announcement, the company noted that while designing its onsite Blue Hydrogren fueling tech, PowerTap knew that electricity shortages were a possibility in areas where the hydrogen fueling stations would be installed. To view the full press release, visit http://ibn.fm/so3ub. Also today, the company was featured in a publication from Green Car Stocks, examining how, although electric cars represent the next frontier of vehicular travel, they were bound to disrupt the century-long automotive industry and the manufacturing practices that have now become procedure. Electric vehicles (“EVs”) are powered by a rechargeable battery, unlike conventional vehicles, which rely on internal combustion engines. But the differences between the two types of vehicles don’t stop there.

Clean Power Capital Corp. (CSE: MOVE) (FWB: 2K6) (OTC: MOTNF) is an investment holding company that focuses on investing in and providing early-stage financing to both public and private businesses. Since its original listing with the Canadian Stock Exchange (“CSE”) on January 23, 2019, the company has made investments in a number of different businesses in a variety of industries, including the energy and cannabis sectors. As per the company’s investment policy, its primary goal is to identify and capitalize on high-return investment opportunities presenting the ability to achieve capital appreciation and liquidity.

Clean Power Capital continues to be opportunistic in evaluating prospects across the renewable energy, bio-medical, pharmaceutical and naturopathic sectors, both as an investor and as an operator. The company’s main focus at the moment is to identify such opportunities in the renewable energy industry, including wind, solar and geothermal power and hydrogen and fuel cell technologies, as well as in the biomedical, pharmaceutical and naturopathic sectors, which may include medical or recreational cannabis.

Clean Power Capital currently has 10 investments in a variety of sectors and successfully held nearly C$120 million in investments during the past fiscal year (https://ibn.fm/8oktZ). It returned capital to its shareholders through the distribution of its interest in AgraFlora Organics International Inc. in May 2020 (https://ibn.fm/FRAvq).

Headquartered in Vancouver, British Columbia, Clean Power Capital was formerly named Organic Flower Investments Group Inc. As of November 10, 2020, the company officially changed its name to Clean Power Capital and started trading on the CSE under new ticker symbol ‘MOVE’.

PowerTap Acquisition, Hydrogen Fueling Infrastructure Collaboration

In alignment with its updated investment policy, a reconstituted investment committee and a revised strategy to reflect its focus on the renewable energy market, Clean Power Capital recently completed the acquisition of a 90 percent equity interest in California-based PowerTap Hydrogen Fueling Corp.

Leveraging an impressive portfolio of IP and advanced deployed technologies developed over two decades via substantial investments and partnerships, PowerTap is working on building and expanding a hydrogen filling station network, initially across North America. The company believes that its platform has a significant advantage over other hydrogen fueling stations, because it has a smaller physical footprint and further has the capacity to produce hydrogen fuel on site. As most other hydrogen fueling stations buy hydrogen for storage at higher costs, PowerTap’s model is believed to be exponentially more cost-effective and expandable.

Clean Power Capital’s investment and acquisition will allow PowerTap to step up its efforts and begin work on the hydrogen fueling station network in stages, starting with engineering and design, ongoing development of PowerTap’s third generation product and, finally, licensing & permitting and site preparation. Development is expected to begin in Q4 2021 with engineering and design. Overall, the initial portion of the project is expected to cost $17 million, with Clean Power Capital and PowerTap planning to secure government financing and credit, as well as equity, debt and convertible debt offerings, to fund the infrastructure’s development.

PowerTap technology is already deployed across multiple hydrogen fueling stations in public and private enterprises spanning California, Maryland, Massachusetts and Texas. The company plans to deploy its hydrogen fueling infrastructure at existing truck stops and gas stations across the country, beginning with up to 1,000 stations within the next three to five years. At the moment, there are roughly 70 active hydrogen fueling stations operational and available to consumers in the United States.

Hydrogen Industry Outlook

The project is expected to bring significant opportunities for PowerTap and Clean Power Capital on the fast-growing hydrogen market, driven by a worldwide focus on clean energies and environmentally friendly fueling solutions for the transportation industry.

Hydrogen-powered vehicles come with tremendous advantages over gas, diesel and even electric vehicles in terms of cost per mile, fueling time and driving range, as well as boasting significantly lower emissions. Well-established vehicle manufacturers such as Hyundai, Toyota, Daimler and Volvo are already including hydrogen-powered cars in their product lineups, and Nikola Motors has announced plans to manufacture hydrogen electric long-haul vehicles.

“As an experienced developer of technology in an important area that is finally having its time as a green but also economically compelling energy option, PowerTap is intent on becoming a leading part of the multi-billion dollar hydrogen fueling space,” PowerTap CEO Raghu Kilambi explained in a news release on October 28, 2020 (https://ibn.fm/oaXem).

A recent industry report developed by a coalition of major oil and gas, power, automotive, fuel cell and hydrogen companies indicates that the sector is expected to grow to $140 billion a year in revenue by 2030, creating 700,000 jobs in the U.S. alone (https://ibn.fm/UMI5q). According to Fuel Cell and Hydrogen Energy Association President Morry Markowitz, the sector could expand to $750 billion a year in revenue and 3.4 million jobs by 2050.

The U.S. is already engaged in the hydrogen economy, having more than half of the global number of fuel cell vehicles and investing hundreds of millions of dollars a year, but the country can greatly expand its global energy leadership by scaling up operations in the hydrogen economy, per the industry report.

With the upcoming change in administration in January 2021, the U.S. is expected to renew its commitment to clean energy. Moreover, the U.S. federal government is expected to invest significantly in clean energy and related infrastructure, including hydrogen, according to PowerTap.

“As the U.S. federal government has previously invested in the PowerTap technology, we are optimistic that we will have a seat at the table when USA clean energy/hydrogen infrastructure spending initiatives are designed,” Kilambi added.

Management Team

Joel Dumaresq is the CEO and interim CFO of Clean Power Capital. He is a proven executive with extensive operational and senior management experience in mining, energy and alternative energy, as well as the cannabis and hemp space. Dumaresq began his career in the corporate finance space, having spent 12 years with RBC Dominion Securities. He brings 30 years of experience in the financial sector to the company, has been instrumental in raising over $250 million in venture capital finance, and he has personally managed a number of successful public listings.

Brendan Purdy serves as a director of Clean Power Capital. An experienced businessperson who has led five different companies, Purdy brings years of experience in different industries, including cannabis, blockchain and data security, gaming, mining and energy, and finance and law. He received a graduate degree from the University of Ottawa and an undergraduate degree from the University of Western Ontario.

Theo van der Linde serves as a director of Clean Power Capital. He is a Chartered Accountant with over 20 years extensive experience in finance, reporting, regulatory requirements, public company administration, equity markets and financing of publicly traded companies. He has served as a CFO & Director for a number of TSX Venture Exchange- and Canadian Securities Exchange-listed companies over the past several years. His industry experience spans the financial services, manufacturing, oil & gas, mining and retail industries. More recently, van der Linde has been involved with future use trends of natural resources, as well as other disruptive technologies.

Raghu Kilambi is the CEO and CFO of PowerTap Hydrogen. He is a seasoned investor and entrepreneur with over 25 years of global business experience in public and private investments, building businesses and creating shareholder value. He has raised over $1 billion of equity and debt capital for private and public companies and been involved in many M&A acquisitions and exits.

Clean Power Capital Corp. (OTC: MOTNF), closed Thursday's trading session at $1.539648, off by 1.3046%, on 343068 volume with 302 trades. The average volume for the last 3 months is 221,902 and the stock's 52-week low/high is $0.0315/$2.78999996.

Recent News

Predictive Oncology (NASDAQ: POAI)

The QualityStocks Daily Newsletter would like to spotlight Predictive Oncology (POAI).

Predictive Oncology (NASDAQ: POAI) was featured today in a publication from BioMedWire, examining Cataracts, a common eye disease. While researchers have yet to fully understand how the disease works, plenty of research has been done on this ailment. Recently, a group of researchers at the Technical University of Munich (“TUM”) found that the composition of the protein solution was a factor in the disease. The researchers’ findings go against the field’s popular opinion.

Predictive Oncology (POAI) is a knowledge-driven precision medicine company focused on applying data and artificial intelligence (AI) to personalized medicine and drug discovery. The company applies its smart tumor profiling and AI platform to extensive genomic and biomarker patient data sets to build predictive models of tumor drug response to improve clinical outcomes for the cancer patients of today and tomorrow. The company has several tools that support its mission of bringing precision medicine to the treatment of cancer.

Through its subsidiaries, Predictive Oncology’s portfolio of assets includes the following:

  • A database of clinically validated historical and outcome data from patient tumors
  • An in-house Clinical Laboratory Improvement Amendments (CLIA)-certified lab
  • A “smart” patient-derived tumor profiling platform
  • An in-house bioinformatics artificial intelligence (AI) platform
  • A new computerized approach growing tumors in the lab to rapidly develop patient specific treatment options
  • An FDA-approved fluid collection and disposal system

Using these resources, and in collaboration with key players in the pharmaceutical, diagnostic and biotech industries Predictive Oncology is working to determine the best pathways for more individualized and effective cancer treatment.

Subsidiaries

Predictive Oncology leverages the synergies of its three wholly owned subsidiaries to bring precision medicine to the diagnosis of cancer.

Helomics applies artificial intelligence to its rich data gathered from the company’s trove of more than 150,000 tumors to personalize cancer therapies for patients as well as drive the development of new targeted therapies in collaborations with pharmaceutical companies. This database, the largest of its kind in the world, is comprised of ovarian, head and neck, colon and pancreas tumors. Helomic’s CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient treatment decisions, by providing an evidence-based roadmap for therapy.

In addition to its proprietary precision oncology platform, Helomics offers boutique CRO services that leverage its TruTumor™ patient-derived tumor models coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and an AI-powered proprietary platform (D-CHIP) to provide a tailored solution to its clients’ specific needs.

TumorGenesis is developing a new, rapid approach to growing tumors in the laboratory without the use of rats or mice, allowing for the identification of biomarkers indicative of cancer. This methodology “fools” the tumor into thinking it is still in the body. As a result, the tumor reacts as it naturally would, thereby increasing the accuracy of the biomarker. Once the biomarkers are identified, they can be used in TumorGenesis’ Oncology Capture Technology Platforms which isolate and helps categorize an individual patient’s heterogeneous tumor samples to enable development of patient-specific treatment options.

Skyline Medical’s patented, FDA-cleared STREAMWAY® System is the first true, direct-to-drain fluid disposal system designed specifically for medical applications such as radiology, endoscopy, urology and cystoscopy procedures. The STREAMWAY system is changing the way healthcare facilities collect and dispose of potentially infectious waste fluid by connecting directly to a facility’s plumbing system to automate the collection, measurement and disposal of waste fluids.

The STREAMWAY minimizes human intervention for better safety and improves compliance with Occupational Safety and Health Administration (OSHA) and other regulatory agency safety guidelines. The STREAMWAY eliminates canisters, carts and evacuated bottles, which reduces overhead costs and minimizes environmental impact by helping to eliminate the approximately 50 million potentially disease-infected canisters that go into landfills annually in the United Sates.

Skyline has achieved sales in five of the seven continents through both direct sales and distributor partners.

Competitive Advantage

Precision medicine has become the holy grail of cancer therapeutics. Data driven predictive models of tumors and their responses are critical in both new drug development and individualized patient treatment. The race has begun to model various tumors, which takes 5 to 7 years of clinical evaluation to establish historical and outcome data.

Predictive Oncology enjoys significant competitive advantage. The company already has a vast historical collection of tumors and related data, plus the ability to obtain existing associated outcome data. While others wait for outcome data, Predictive Oncology is in a unique and powerful position, working to deliver the promise of precision medicine to reality. Predictive Oncology already has the clinical data, including how a tumor responded to certain drugs, an in-house bioinformatics AI platform, and only needs to do the tumor sequencing. The significance is underscored by the collaboration with UPMC Magee-Women’s Hospital, designed to reveal which mutations responded to which drug then develop powerful predictive models for future testing and treatment.

Leadership Team

Dr. Carl Schwartz was appointed to Skyline Medical’s board of directors in March 2015 and became interim president and CEO in May 2016. Dr. Schwartz became CEO of Plastics Research Corporation in 1988, leading the company to become the largest manufacturer of structural foam molding products in the U.S. with more than $60 million in revenues and 300 employees by the time he retired in 2001. He holds a bachelor’s degree and DDS degree from the University of Detroit.

CFO Bob Myers has over 30 years of experience in multiple industries focusing on medical device service and manufacturing. He has spent much of his career as a CFO and controller. Myers holds an MBA in Finance from Adelphi University and a BBA in public accounting from Hofstra University.

Gerald Vardzel, President of Helomics, has over 25 years of healthcare executive management experience developing and implementing commercialization strategies and models for technology launches. His Go-To-Market expertise includes equity financing, strategic planning, market intelligence, M&A, and new market development in both start-up and established settings including fortune 500 market leaders. He has developed innovative solutions for both CLIA and FDA regulatory paths defining the delivery chains from discovery to clinical acceptance. Mr. Vardzel also has significant experience designing and implementing sales and marketing programs tailored not only to expand market share, but to empirically assess client satisfaction, strengthen business processes, and maximize profitability. Mr. Vardzel was previously Vice President of Corporate Development and Strategic Initiatives at Global Specimen Solutions. Furthermore, as an executive affiliate to the healthcare industry, he routinely consults for several small-to-mid sized private equity firms advising on, in part, the feasibility of acquisition targets. Mr. Vardzel graduated from the University of Pittsburgh.

Dr. Mark Collins, Chief Information Officer of Helomics, has held multiple executive roles in a variety of discovery, informatics and bioinformatics functions within global pharma, and founded three startup software companies in the machine learning and drug discovery space. In 2001, Dr. Collins worked for Cellomics (now part of Thermo Fisher Scientific), where he played a pivotal role in establishing the High-Content Cell Analysis market, building and commercializing several key informatics and bioinformatics products. After leaving Thermo Fisher, Dr. Collins developed and commercialized informatics solutions for clinical and translational research, specifically in the specimen tracking, omics data management and NGS analysis space, through key roles at BioFortis, Global Specimens Solutions and Genedata. Dr. Collins received his undergraduate degree in Applied Science from the University of Wolverhampton, UK and his Ph.D. in Microbiology from the University of Surrey, UK.

Predictive Oncology (POAI), closed Thursday's trading session at $1.47, off by 6.3694%, on 4846873 volume with 12,760 trades. The average volume for the last 3 months is 4,092,358 and the stock's 52-week low/high is $0.629999995/$4.42000007.

Recent News

Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF)

The QualityStocks Daily Newsletter would like to spotlight Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF).

Imagin Medical (CSE: IME) (OTCQB: IMEXF), a surgical imaging company, is focused on changing the standards of visualizing cancer during minimally invasive procedures. The company’s innovative technology has the potential to revolutionize the current standard of care for bladder cancer patients. Imagin Medical’s i/Blue Imaging(TM) System is based on advanced optics and light sensors and uses patented ultrasensitive imaging technology. To view the full article, visit: https://ibn.fm/QBJwv

Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) is a surgical imaging company focused on establishing a new standard of care in visualizing cancer during minimally invasive procedures. Its initial focus is on bladder cancer.

The company’s first product is the i/Blue Imaging™ System, based on advanced optics and light sensors and employing patented ultrasensitive imaging technology. Imagin Medical believes the system can significantly improve surgeons’ ability to visualize and remove cancer cells.

Founded in 2016 and headquartered in Boston, Massachusetts, the company works to enhance its market potential by expanding its technology to multiple endoscopic indications, such as laparoscopic, colorectal and thoracic procedures, accommodating multiple contrast agents and illumination sources.

i/Blue Imaging™ System

The conventional method used for visualizing bladder cancer during surgery is an endoscopic procedure called a cystoscopy. This procedure uses white light to illuminate the bladder. White light has been used for decades and is the standard for more than 90% of the market. Blue light cystoscopy uses blue-filtered white light, which addresses the limitations of white light (such as detecting flat tumors and the fine edges that may result in cancerous cells being left behind during removal).

Blue light uses a contrast agent that causes cancer cells to fluoresce when illuminated. Surgeons are then able to more effectively visualize and resect the margins of bladder tumors to reduce the risk of recurrence. Notably, the use of the white light is still necessary during a blue-light procedure so that the surgeon can orient their position within the bladder.

Imagin Medical’s i/Blue Imaging System addresses the limitations of both white and blue light cystoscopies. The i/Blue System combines the white and blue light with an FDA-approved imaging agent and simultaneously displays side-by-side images in real-time, without the necessity to switch back and forth between the two images.

The i/Blue Imaging System is unlike other methods available on the market today. It is external to the body and can attach to almost any endoscope model currently in use. This way, hospitals adopting Imagin Medical’s technology have the ability to use their current endoscopes without the need to purchase new equipment.

Bladder Cancer Prevalence

The company’s initial focus is bladder cancer, which is the sixth most prevalent form of cancer in the United States. In 2020, the number of new bladder cancer cases is expected to total 81,400, accounting for 4.5 percent of all new cancers diagnosed. The death rate in 2020 for cancer deaths associated with the bladder is forecast at 17,980, or 3% of all cancer-related deaths (https://ibn.fm/qLi3l).

Bladder cancer also has one of the highest recurrence rates among all forms of cancer, leaving about 600,000 people in fear that their cancer will return, according to Imagin Medical. The company is committed to addressing this issue, and i/Blue demonstrations have indicated that the use of both white and blue light can enhance accuracy of detection and removal of cancer cells, potentially lowering recurrence rates.

Based on Verified Market Research, the global bladder cancer research market was valued at $3.43 billion in 2018. It is estimated to grow with a CAGR of 4.03% through 2026, resulting in a projected $4.71 billion market (https://ibn.fm/rI7G6).

Management Team

E. James Hutchens is the Chief Executive Officer of Imagin Medical Inc. He is a proven entrepreneur with over 30 years of experience in management in the medical technology industry. Hutchens served as a managing partner with Origin Partners, a $55 million early-stage venture capital fund. He was also the founder and CEO of both Microsurge Inc. (a venture-backed minimally invasive surgical company) and Choice Therapeutics (an advanced wound-care company). He is a former member of the Board of Directors of the Brigham and Women’s and Faulkner hospitals. Hutchins holds a BS in Business Administration from Boston University.

John Vacha is the company’s Chief Financial Officer. He has 20 years of experience in the health care industry. Prior to Medtronic’s acquisition of Intact Medical Corp. in 2017, Vacha was the company’s President, CEO and a board member for seven years. He is a licensed CPA in Massachusetts. Vacha has an MBA and an MS in Accounting from Northeastern University in Boston. He is also a serving member of the Board of Directors at the South Boston Health Center. He currently has two patents in electrosurgical instrumentation.

Michael G. Vergano is the Director of Operations of Imagin Medical. He has been the President of The Harvest Group Inc. since 1998, where he has provided consultant services for startups and major corporations. Vergano has over 30 years of experience in the medical device industry. He has held management positions at Microsurge Inc., Ciba Corning Diagnostics and Boston Scientific Corp. He is currently the holder of 11 medical device patents and holds a BS in Mechanical Engineering from Tufts University.

Pam Papineau is the company’s Director of Regulatory Affairs. She has over 30 years of experience in quality and regulatory affairs with Boston Scientific, Baxter and Cogentix. She has served as a consultant on various devices including imaging, endoscopy, orthopedic, GI/GU and cardiovascular applications. Papineau has successfully prepared dozens of FDA pre-market and EU submissions to support CE marking of a broad spectrum of medical devices. She is an ASQ Certified Quality Engineer, a Certified Biomedical Auditor, a Certified Quality Auditor and an ISO 13485:2016 Lead Auditor, and she is certified by the Regulatory Affairs Professional Society – U.S., EU and Canada. Papineau works with the company’s legal counsel to prepare pre-submission meetings with the FDA and activities through the regulatory approval process.

Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF), closed Thursday's trading session at $0.6702, off by 5.6189%, on 38180 volume with 18 trades. The average volume for the last 3 months is 44,452 and the stock's 52-week low/high is $0.200000002/$1.16999995.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

closed Monday's trading